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ABSTRACT 
The purpose of this study was to evaluate 14-gauge stereotactic core needle biopsies 
(SCNB) obtained by an add-on biopsy device in the diagnosis of mammographically detected 
non-palpable breast lesions and also to investigate the use of add-on stereotactic device for 
localizing lesions detected only with galactography. In a study of invasive breast cancers, 14 
gauge core biopsies were compared to surgical specimens in the assessment of three 
clinically important prognostic factors (estrogen receptors (ER), progersterone receptors (PR) 
and human epidermal growth factor (HER-2)). 
Altogether 221 patients with 231 breast lesions were included in the study of SCNBs and 9 
patients were included in the wire-localization study. The learning curve was evaluated by 
comparing the first five biopsies of each of the five radiologists involved in this study with 
their later biopsies. During the study period between June 1998 and January 2001, core 
samples were collected in three different containers as follows: the first sample (the central 
biopsy) was collected into container A, the second and the third samples (obtained 2 mm 
from the centre of the lesion) into container B, and all additional samples into container C. 
Histological evaluation and report were performed for each container separately. After core 
biopsy, all women whose biopsy result indicated the presence of invasive carcinoma or DCIS 
(ductal carcinoma in situ) underwent surgical treatment. High-risk lesions, such as ADH 
(atypical ductal hyperplasia) and radial scars were also surgically resected, as were benign 
lesions with discordant mammographic findings. All other lesions with benign biopsy results 
were recommended for mammographic follow-up at 1 year and 2 years.  
The results support the existence of a learning curve in the biopsy of microcalcifications. The 
sensitivity of 100% for masses and 91% for microcalcifications was reached with multiple 
samples (more than three). Four false negative cases decreasing the sensitivity in 
microcalcifications were ADH in three cases and there was one lesion with discordant 
mammographic and SCNB-findings. Stereotactic 14-gauge core biopsy seems to be at least 
as sensitive as a surgical specimen in the assessment of ER, PR and HER-2. Three cores 
are needed for reliable assessment of HER-2 after adding CISH and more than 3 cores for 
PR, possibly due to tissue heterogeneity. For ER sensitivity remained lower, 95%, even in 
multiple cores, therefore ER-negative cases should be further investigated from surgical 
specimens. 
Stereotactic guided wire-localication can be successfully performed for mammographically 
invisible intraductal lesions by using galactography in the same session to visualize the 
target. 
The diagnostic accuracy, false negative rate and underestimations of 14-g core biopsies 
obtained by an add-on stereotactic device in this study are comparable to those obtained by 
a dedicated prone device according to the literature in the biopsy of non-palpable breast 
lesions. In addition, an add-on device can be used for wire-localization of mammographically 
invisible lesions under galactography guidance. 
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1. INTRODUCTION  
 
Breast cancer is the most common cancer in women all over the world [1]. Mass 
screening programmes are capable of detecting increasing number of clinically 
occult, non-palpable breast lesions. This has created the need to develop minimally 
invasive, biopsy methods as an alternative for diagnostic surgical biopsy to achieve a 
definitive diagnosis. Surgical biopsy is costly and associated with a relative morbidity. 
Imaging guided biopsies can obviate the need for unnecessary surgery in women 
with benign lesions [2]. In case of malignancy needle biopsy provides special 
diagnosis and also preoperative determination of histological prognostic factors such 
as grade, type, and invasion of neoplasm, as well as ER, PR and HER-2 status is 
often possible. This enables planning of extent of surgery before operation and also 
planning of neo-adjuvant treatment, if needed. Imaging guided breast biopsy can be 
performed under local anesthesia; it is quick to perform, and does not cause any 
deformation or disturbing scarring to the breast [3, 4]. It also reduces the costs for the 
diagnosis [5-7].  
Imaging guided breast biopsy is most often performed under ultrasonographic [4, 
7] or stereotactic guidance [8-12] and for specific indications, under MRI guidance 
[13, 14]. Fine needle aspiration cytology has in most centres been replaced by 
cutting needles (automated large core needles) [15] and lately directional vacuum 
assisted devices [16, 17]. 
For the past decade, stereotactic core needle biopsy (SCNB), first reported by 
Parker et al [12] has been increasingly used for confirming the histologic diagnosis of 
non-palpable breast leasions. Several reports of 14-gauge stereotactic core needle 
biopsy have been published with sensitivities for detection of malignancy ranging 
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from 87% to 96% [8, 11, 12, 18, 19] and with false negative rates of 3-7% [8, 9, 11, 
18]. Almost all of these studies have been performed using a dedicated prone biopsy 
table. The biopsy with dedicated prone equipment is better tolerated by the patient 
than biopsy using an add-on device with the patient in a sitting position. With the 
patient in a prone position, vasovagal reactions and patient motion are eliminated. 
However, a dedicated biopsy table is expensive and occupies a great deal of space 
[20, 21]. 
Add-on unit with conventional mammography equipment is less expensive, does 
not need extra room and furthermore, the equipments can be used for 
mammography when not needed for breast biopsy [22]. It may therefore be the first 
choice for many smaller centres diagnosing breast cancer. Studies for add-on device 
are scanty. The diagnostic accuracy, the number of cores needed, underestimations, 
false negative rate, learning curve and prognostic factor assessment need to be 
investigated with reference to surgical samples or with sufficient follow-up to validate 
the results obtained with an add-on device for diagnosing non-palpable breast 
lesions.  
Occasionally, surgery is needed to achieve a diagnosis of a breast lesion. Non-
palpable lesions can be localized prior surgery by a guide-wire under sonography or 
stereotactic guidance. Spontaneous clear, serous (yellowish clear) or blood 
containing discharge secreting unilaterally from one duct orifice is most commonly 
caused by a benign intraductal papilloma, but in 10-15% carcinoma can be found 
[23-25]. These lesions are therefore usually regarded as an indication for surgical 
removal, which is also the treatment for the symptom. The lesions that present with 
nipple discharge are typically not visible on mammography or ultrasonography, but 
can be detected on galactography [26, 27]. As a consequence, the usual methods for 
21 
guiding biopsy or preoperative localization are not applicable. Retroareolar lesions 
can be detected perioperatively by methylene dye staining of the duct. Distant lesions 
may be difficult to localize despite methylene dye staining as the dye quickly diffuses 
from ducts into breast tissue [28]. This may thus lead to excessive resection or failure 
to remove the lesion. Also in cases with intermittent discharge where no nipple 
discharge is detected during the operation, it may be impossible to localize the 
discharging duct. There is a need for additional methods for localizing distant 
intraductal lesions and lesions causing intermittent discharge.  
22 
2. REVIEW OF THE LITERATURE 
 
2.1. Breast cancer epidemiology 
Breast cancer is the most common malignancy in women all over the world and 
accounts for 23% of all female cancers [1]. According to the Finnish Cancer Register, 
the annual age-adjusted breast cancer incidence has increased over the past years. 
During time period 1962-1996 annual incidence increased from 29.9 to 71.9 [29]. 
Worldwide, the overall annual increase in incidence rate has been 0.5% since 1990. 
In 2006, the number of new breast cancer cases in Finland was around 4060 [29]. 
The aetiology of breast cancer is multifactorial. Environmental risk factors are 
believed to be of greater importance than genetic factors. This is evident from the 
studies with emigrants, which show that incidence rises following migration from low 
to high incidence countries [30]. Only around 10% of breast cancer cases in Western 
countries are thought to be due to a genetic predisposition. 
The mortality of breast cancer rose from 1951 to 1990 but has been falling 
thereafter in most European countries, Australia and in the United States [31]. The 
reasons for the decline in mortality include widespread mammographic screening, 
precise diagnosis and effective treatment modalities [32]. The average survival rate 
in developed countries is 73% whereas in the developing countries it is only 57%. 
With 411 000 annual deaths, breast cancer is the leading cause of cancer mortality 
(14%) in women [1].  
 
2.2. Pathogenesis of breast cancer 
A definitive progression model from healthy breast tissue to invasive carcinoma 
has not yet been determined. The preneoplastic potential of benign, proliferative 
lesions of the breast is still a matter of debate [31] According to the WHO Working 
23 
Group, intraductal proliferative lesions are defined as a group of cytologically and 
architecturally diverse proliferations typically originating from the terminal ductal 
lobular unit (TDLU) and confined to the mammary duct lobular system. They are 
associated with an increased risk, albeit of greatly different magnitudes, for the 
subsequent development of invasive carcinoma [33]. Intraductal proliferative lesions 
have traditionally been divided into three categories: unusual ductal hyperplasia 
(UDH), with relative risk of 1.5-2.0 times that for reference population [34, 35], 
atypical ductal hyperplasia (ADH), relative risk 4-5, range 2.4-13 and ductal 
carcinoma in situ (DCIS), with relative risk of 8-10 [34]. Currently flat epithelial 
hyperplasia is defined as a presumably neoplastic intraductal proliferation, whose risk 
of malignant transformation is still unknown [36]. 
 
2.3. Histopathology of carcinomas 
Breast cancers are divided into in situ carcinomas and invasive carcinomas 
according to their capability for infiltrating adjacent tissues and metastasing. Both in 
situ and invasive breast carcinoma can be divided into subtypes according to their 
histopathologic properties [33, 37].  
 
2.3.1. Ductal carcinoma in situ (DCIS) 
DCIS is a neoplastic intraductal lesion, characterized by increased epithelial 
proliferation, cellular atypia and an inherent tendency for progression to invasive 
breast carcinoma [33]. The site of origin for DCIS is the TDLU from where it spreads 
inside the ductal structures and extends into the epithelium of lobular glands. 
Detection of DCIS has increased since the introduction of widespread screening 
mammography in the early 80´s. In current screening programs, 10-30% of all 
24 
detected malignancies are DCIS [38, 39]. In mammography, 73-98% of DCIS cases 
are evident as microcalcifications [40-42]. Lesions that lack mammographic evidence 
of microcalcifications are either mammographically occult or present as 
circumscribed or nodular masses, architectural distortions or non-specific densities 
[41]. If treated, prognosis of DCIS is excellent. Of women diagnosed with DCIS 
between 1984 and 1989, 1.9% died of breast cancer at 10 years [43].  
 
2.3.2. Invasive ductal carcinoma, not otherwise specified (NOS) 
According to the WHO characterisation, invasive ductal carcinoma, not otherwise 
specified (ductal NOS) is a heterogenous group of tumours that fails to exhibit 
sufficient characteristics to achieve classification as a specific histological type, such 
as lobular or tubular carcinoma [33]. It comprises the largest group, 40% to 75% of 
malignant breast tumours [33, 44]. Typically, the mammographic characteristics of 
ductal carcinoma include central tumour mass with radiating spicules; associated 
microcalcifications are common [45]. Ductal carcinoma can also appear as a 
mammographic density with irregular, nodular or circumscribed contour or as a 
cluster of microcalcifications [45]. The 5-year relative survival of the patients with 
ductal carcinoma is 79% [44].  
 
2.3.3. Invasive lobular carcinoma 
Invasive lobular carcinoma accounts for 5% to 15% of invasive breast 
carcinomas [46]. The microscopical growing pattern of invasive lobular carcinoma 
forms thread-like strands of tumour cells loosely dispersed throughout the fibrous 
stroma [37]. Both macroscopically and mammographically invasive lobular 
carcinomas are often poorly delimited and difficult to define [47]. A tendency for 
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multicentricity [48] and bilaterality [47] has been reported. The average 5-year 
survival of invasive lobular carcinoma is 86% [49]. 
 
2.3.4. Other types of invasive carcinoma 
Tubular carcinoma, invasive cribriform carcinoma, medullary carcinoma and 
mucinous carcinoma are usually histopathologically well differentiated and are 
mammographically detectable as either a spiculated mass (tubular and crifriform 
carcinoma) [50, 51] or a well delineated mass (medullary and mucinous carcinoma) 
[33, 52]. These tumours have a favourable 10-year prognosis ranging from 90% to 
100% [53, 54]. Inflammatory carcinoma is a particular form of breast carcinoma with 
a poor 5-year survival of 18% to 41% [44, 55, 56].  
 
2.4. Histopathology of high risk lesions 
High risk lesions are ductal and lobular proliferations that have been shown to 
have a statistical association with increased risk of subsequent breast cancer or be 
due to genetic alterations or mutations similar to those present in DCIS or infiltrating 
carcinoma of the breast [57]. 
 
2.4.1. Atypical ductal hyperplasia (ADH) 
The diagnosis of ADH is based on morphologic criteria with a cytologic atypia or 
clonal appearance and structural rigidity and geometric spaces similar to those seen 
in low-grade DCIS. In ADH, these changes involve only part of a duct space or an 
area smaller than 2 mm [58, 59]. ADH is the most common high-risk lesion 
accounting for 5% of all breast biopsies [60]. ADH can coexist with both in situ and 
invasive carcinomas.  
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2.4.2. Lobular neoplasia 
A spectrum of proliferative changes from ALH to LCIS in the lobule portion of 
TDLU can be called lobular neoplasia. The distinction between ALH and LCIS is 
based on the degree of involvement of the lobular units by the characteristic loosely 
cohesive monomorphic cells [61]. The incidence of LCIS in otherwise benign breast 
biopsy is between 0.5% and 3.8% [62, 63]. Lobular neoplasia has been thought to be 
an incidental finding at breast biopsy, without a mammographic correlate [64]. 
However, it has been noted that it can also appear as a cluster of microcalcifications 
[65, 66]. Lobular neoplasia is frequently multifocal and bilateral and is associated with 
increased incidence of malignancy in both breasts [64].  
 
2.4.3. Radial scar 
The radial scar and its larger variant, the complex sclerosing lesion, may arise 
from any of the benign proliferative lesions (adenosis, papilloma, usual and atypical 
hyperplasia) [57]. In the mammography it appears as an area of architectural 
distortion without any central mass [67]. Due to the reported association with tubular 
or ductal carcinoma or high risk lesions [68, 69], surgical excision is usually 
recommended. 
 
2.5. Prognostic factors of breast cancer 
The presence of histologically assessed axillary lymph node metastasis is the 
single most important predictor of postreatment breast cancer recurrence and death 
[70]. Also young age (under 40 years) and tumour size are independent prognostic 
indicators for breast cancer survival [71]. Survival rates for women with invasive 
breast cancer are about 90% for tumours smaller than 1 cm, 80% for tumours 1.0 to 
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1.9 cm, 70% for tumours 2.0 to 4.9 cm and 60% for tumours larger than 5 cm [72]. 
Tumour staging (Table 1) aids to predict prognosis of breast cancer. It is based on 
the tumour, nodes and metastases (TNM) classification (Table 2) of International 
Union Against Cancer (UICC) [73], which can be assessed either clinically (TNM) or 
pathologically (pTNM). 
 
 
Table 1. Stage according to UICC classification 
(2002), with reference to the TNM classification 
presented in Table 2 
Stage T N M 
0 Tis N0 M0 
I T1 N0 M0 
IIA T0-1 
T2 
N1 
N0 
M0 
M0 
IIB T2 
T3 
N1 
N0 
M0 
M0 
IIIA T0-2 
T3 
N2 
N1-2 
M0 
M0 
IIIB T4 N0-2 M0 
IIIC T0-4 N3 M0 
IV T0-4 N0-3 M1 
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Table 2. Tumour-Node-Metastasis (TNM) classification of breast tumours 
according to UICC, 2002 
Category Description 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ  
T1 Tumour 2 cm or less in greatest dimension 
T2 Tumour more than 2 cm but not more than 5 cm in greatest dimension 
T3 Tumour more than 5 cm in greatest dimension 
T4 Tumour of any size with direct extension to chest wall or skin only 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastases 
N1 Metastasis in movable ipsilateral axillary lymph node(s) 
N2 Metastasis in fixed ipsilateral axillary lymph node(s) or clinically 
apparent ipsilateral internal mammary lymph node(s) in the absence of 
clinically evident axillary lymph node metastasis 
N3 Metastasis in ipsilateral infraclavicular lymph node(s) with or without 
axillary lymph node involvement; or in clinically apparent ipsilateral 
internal mammary lymph node(s) in the presence of clinically evident 
axillary lymph node metastasis; or metastasis in ipsilateral 
supraclavicular lymph node(s) with or without axillary or internal 
mammary lymph node involvement 
MX Distant metastasis cannot be asessed 
M0 No distant metastasis 
M1 Distant metastasis 
 
 
2.5.1. Estrogen receptor (ER) and progesterone receptor (PR) expression 
Hormone receptors are proteins that bind and mediate the cellular effects of 
circulating hormones. Since expression of PR is estrogen regulated, most PR 
positive carcinomas are also ER positive. Less than 10% of carcinomas are ER 
negative and PR positive [37]. The expression of estrogen and progesterone 
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receptors in the tumour tissue predicts a good response to hormonal therapy of 
breast cancer in both an adjuvant setting and in metastatic disease [74, 75]. Positive 
ER and/or PR status is also related to significantly prolonged disease-free survival 
and overall survival [76]. 
Hormone receptor assessments are increasingly performed by 
immunohistochemisty. The immunohistochemical method makes it possible to 
observe the specific cellular site of hormone receptor expression and to distinguish 
ER/PR activity in carcinoma cells from benign epithelium. The method is applicable 
both for core samples and surgical specimens [37]. 
 
2.5.2. Human epidermal growth factor (HER-2) 
Proto-oncogenes are normal genes involved in cell growth and proliferation and 
their mutated forms promote neoplastic transformation. HER-2, the encoded product 
of proto-oncogene ERBB2/HER-2/Neu belongs to a human epidermal growth factor 
receptor (EGFR) family [77, 78]. HER-2 is expressed in a range of normal adult and 
foetal epithelia and plays an important role of growth and development [79]. In 
cancer, HER-2 overexpression/amplification has been observed in a variety of 
tumours including 9 to 30 percent of breast cancers [80-82]. Overexpression of the 
HER-2 protein, amplification of the HER-2 gene, or both are associated with 
aggressive behaviour of cancer cells, such as enhanced growth and proliferation and 
increased invasive and metastatic capabilities [80, 83]. In patients with invasive 
breast carcinoma, HER-2 amplification has been shown to be associated with a 
significant reduction in disease-free survival in node-positive patients [80, 84], This 
phenomenon has been related to a response to trastuzumab anticancer therapy (a 
humanised recombinant monoclonal IgG1 antibody against HER-2) [80, 85, 86]. In 
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metastatic disease, trastuzumab in combination with chemotherapy has achieved a 
response rate of 50% and prolonged survival [87]. A significant improvement in both 
recurrence free survival and in overall survival with trastuzumab has been reported 
also in adjuvant setting for early breast cancer [88-90].  
The majority of HER-2 studies have been performed using HER-2 
immunohistochemistry (IHC) [91]. With IHC, there are problems with standardization 
in slide scoring [92, 93], with a tendency for false positive HER-2 assessments, 
especially with 2+ results depending on the antibody used [94]. Therefore, it is 
recommended to confirm IHC positive results by fluorescence in situ hybridisation 
(FISH) [82], which is the gold standard for HER-2 assessment. The latter method has 
the advantages of a more objective scoring system, where all non-neoplastic cells 
within the specimen serve as an internal control [95]. In addition to FISH, there is 
another relatively new method for detection of gene amplification, chromogenic in situ 
hybridisation (CISH). CISH uses a peroxidase reaction, which can be viewed with a 
standard light microscope. It also has built-in internal control and ensures reliable 
recognition of the invasive carcinoma area by light microscopy. The CISH staining 
remains in the slides and can be reassessed if necessary [95]. An excellent 
concordance has been found between CISH and FISH [96-98]. 
 
2.6. Breast imaging 
Suspicious breast abnormalities should always be investigated by triple 
assessment: clinical examination, imaging (mammography and ultrasonography) and 
tissue sampling (needle biopsy) [33, 99]. 
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2.6.1. Mammography  
Mammography is the single most important imaging method of breast diseases 
which can be used for either screening or for clinical purposes. It is the first line 
imaging method for symptomatic patients [100, 101].  
 
2.6.1.1. Screening mammography 
Screening refers to examinations performed regularly on asymptomatic persons. 
In Europe, this implies a program in which women are systematically invited to 
participate in mammography imaging according to a population registry with the goal 
to detect breast cancer at an early, clinically occult stage [28]. 
Large randomized studies show about a 30% reduction in breast cancer mortality 
and about a 40% reduction in those receiving screening [102-105]. The decrease in 
mortality is attributable to a decrease in the size of cancers detected in the screening 
mammography [106, 107]. Screening is most advantageous in women older than 50 
years. However, it has been shown that screening can reduce mortality significantly 
also in the group of women aged 40-49 years [108].  
Recommendations for screening vary on the basis of the trials. The American 
cancer society has recommended yearly mammographic screening and physical 
examination beginning at age 40 [109]. The European Union recommends an 
organized, quality controlled mammography screening programme for women aged 
50-69 years at 2-3 years intervals. If screening is offered to women aged 40-49 
years, they should be informed about the possible benefits and adverse effects of 
screening [110]. In Finland, a nationwide screening programme arranged in two year 
intervals was started for women at the age of 50-59 years in 1987 and gradually 
implemented [111]. In 2006, a decision to offer mammografic screening was 
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expanded for women at the age of 50-69 years [112]. The participation rate in 1987-
1997 has been high, 89%. The recall rate decreased from 4.7% to 3.3% and the 
biopsy referral from 1.1% to 0.6% in the first three years [113]. 
 
2.6.1.2. Sensitivity of mammography  
The sensitivity of mammography to detect cancer ranges from 63% to 98%. In 
fatty breasts, the sensitivity can be as high as 98% to 100% [101, 114] but in dense 
breasts, sensitivities as low as 30% to 48% have been reported [101, 114, 115]. The 
density of breast parenchyma decreases with age, increasing the sensitivity of 
mammography [116]. Mammography is the most sensitive imaging method at 
detecting microcalcifications [40].  
 
2.6.1.3. Specificity of mammography  
The majority of findings in mammography is non-specific and only permits 
likelihood statements [117, 118]. In addition to better sensitivity, also specificity 
(characterization of e.g. density and contours of the lesions) is higher in fatty breasts 
[114, 117, 118]. Most small, nonpalpable carcinomas present as non-specific 
changes [108, 119-121]. 
 
2.6.1.4. BI-RADS-classification 
To improve quality of mammographic reporting and interpretations and to 
facilitate communication between radiologists and clinicians, Breast Imaging, 
Reporting and Data system (BI-RADS) was designed by American College of 
Radiology [122, 123]. The use of BI-RADS-classification gives consistent guidelines 
to evaluate masses, microcalcifications, architectural distortions, asymmetries and 
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associated findings as skin or nipple retraction, skin thickening, trabecular thickening, 
skin lesions and axillary adenopathy and give further management recommendations 
[122]. A definite diagnosis of a benign lesion (BI-RADS 2) is possible for an oil cyst, a 
hamartoma, a lipoma, a typically calcified fibroadenoma or an intramammary lymph 
node. In the case of a low density well circumscribed mass, a benign diagnosis (BI-
RADS 2) can be proposed in 98% of the cases [117, 118]. For BI-RADS 3 lesions, 
short interval follow-up is suggested. BI-RADS 4 and 5 are suspicious for malignancy 
and should therefore be confirmed by breast biopsy (Table 3). 
 
Table 3. BI-RADS-classification 
Category  Risk of 
malignancy 
BI-RADS 0 Incomplete, additional evaluation needed (additional 
mammographic views, ultrasound) 
 
BI-RADS 1 Negative, no lesions found, routine follow-up  
BI-RADS 2 Benign, routine follow-up  
BI-RADS 3 Propably benign, short interval follow-up (e.g. 6 
months) 
2% 
BI-RADS 4 Suspicious  
4A Low suspicion, consider biopsy 6% 
4B Intermediate suspicion: Biopsy 15% 
4C Moderate suscipion: Biopsy 53% 
BI-RADS 5 Highly suggestive of malignancy: Biopsy 81-91% 
BI-RADS 6 Known biopsy proven malignancy  
Source: references [120, 122, 124] 
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2.6.2. Ultrasonography 
Currently, ultrasonography is an adjunctive diagnostic tool indicated for 
evaluation of specific abnormalities detected by either clinical examination or by 
mammography [125] or for guiding percutaneous biopsy and localization [28]. In the 
imaging of young women under 30 years, ultrasonography is used as the first 
imaging study in the evaluation of a palpable mass [28]. Recently, with the 
introduction of high frequency (>7 mHz) transducers, the differentiation between solid 
and cystic masses has become more reliable than was the case with older 
equipment and the characterization of solid masses as benign or suggestive of 
malignancy can now be established with confidence [126]. Recent studies have 
demonstrated the ability of breast ultrasonography to detect small, 
mammographically occult breast carcinomas in women with dense breast tissue 
[127, 128]. A cancer detection rate of 0.3-0.46% has been reported, similar to that of 
mammographic screening [127, 128]. 
 
2.6.3. Galactography 
Spontaneous clear, serous (yellowish, clear), or blood-containing nipple 
discharge from one duct orifice is an indication for galactography [28]. This kind of 
discharge is most commonly caused by a benign intraductal papilloma; however 
carcinoma is found in 10-15% of cases [23-25] Lesions causing nipple discharge are 
usually not visible on mammography or ultrasonography [26, 27]. In galactography, 
after injecting contrast media into the secreting duct, orthogonal microfocus 
magnification mammography images are obtained [129]. Intraductal lesions are 
classically visualized as a filling defect or a cut-off appearance of the duct. However, 
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these findings are non-specific and need to be further investigated by core biopsy or 
by surgical excision to exclude the possibility of cancer.  
 
2.6.4. Magnetic resonance imaging (MRI) 
Contrast enhanced MRI with its sensitivity of 88% to 97% is the most sensitive 
additional imaging method for detecting invasive breast cancer [130, 131] and DCIS 
[104]. Because of relatively low specificity (30-67%) [130, 131] the use of MRI should 
be limited to high risk patients and to questions that cannot be reliably answered by 
conventional imaging methods or by percutaneous biopsy [132].  
The use of breast MRI has been reported in a variety of clinical situations. Breast 
MRI has been shown to be superior to physical examination, mammography and 
ultrasound in the evaluation of tumor size, multifocality and multicentricity of breast 
cancer [133, 134], especially in patients with invasive lobular carcinoma [134]. Other 
indications for breast MRI include the diagnosis of rupture of a silicone implant, 
differential diagnosis between scar and recurrence after breast conserving therapy 
or, monitoring of neoadjuvant chemotherapy and the search for the primary tumour in 
cases of lymph node or distant metastases and suspicion of breast cancer [28]. 
Although MRI is not suitable for screening of the general population, due to its lower 
specificity and high cost, encouraging preliminary reports have provided evidence 
that MRI can be valuable in screening women with a high risk of developing breast 
cancer [135]. 
 
2.7. Imaging guided breast biopsy 
Traditionally, open surgical breast biopsy has been the gold standard in 
diagnosing breast lesions; non-palpable lesions undergo open biopsy after 
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ultrasonography or mammography guided wire localization. The costs and relative 
morbidity associated with the surgery in conjunction with detection of large number of 
non-palpable breast lesions on screening programmes have lead to the development 
of percutaneous imaging guided breast biopsy methods to replace surgical biopsies. 
Imaging guided breast biopsy is most often performed under ultrasonographic [4, 7, 
136] or stereotactic guidance [8-12] and for specific indications, under MRI guidance 
[13, 14]. Complications are rare, <2% for core biopsies [137, 138] and 4% for vacuum 
assisted biopsies [139]; the complications include bleeding, hematomas, vasovagal 
reactions and infections. Early work with percutaneous breast biopsy involved fine 
needle aspiration (FNA) which has in most centres been replaced by cutting needles 
(automated large core needles) [15] and recently by directional vacuum assisted 
devices [16, 17, 28]. 
 
2.7.1 Ultrasonographic guidance 
Ultrasonographic guidance may be regarded as the first line method for 
percutaneous biopsy of lesions visible by ultrasonography in terms of real time 
visualisation of the needle, patient comfort, lack of ionizing radiation, and low cost [4, 
7]. With the help of ultrasonography, access to all areas of breast and axilla, even in 
small breasts can be reached [4, 7]. With ultrasonography guided 14-gauge biopsies, 
sensitivities and specificities of 100% have been reported [4, 140]. However, 
microcalcifications and a small subset of masses cannot be reliably detected by 
using ultrasonography [28, 141, 142]. The ultrasonography guided biopsies of tiny 
lesions and deep localizations may be complicated and time-consuming and 
stereotactic guidance in these situations may be preferable [28, 141]. 
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2.7.2. Stereotactic guidance 
Stereotaxis is based on the principle that the precise localization of the lesion in 
three dimensions can be calculated on the basis of its parallax shift of position on two 
angled images [17, 28]. At the start of the procedure, a non-angle scout image is 
obtained to document the accurate positioning of the lesion. Two angled images, 15° 
to the right and left along horizontal axis are then obtained. A cursor is placed over 
identical target areas on the angled images to allow the software to calculate x, y and 
z-axes [17, 28].  
There are two major types of stereotactic devices: add-on devices, which are 
attached to ordinary mammography units to convert it into a biopsy guidance system 
and dedicated prone biopsy devices [11, 143]. With the add-on device, the biopsy 
procedure is usually performed with the patient in the sitting position. When not being 
used for biopsies, the mammograpic unit can be used for normal diagnostic 
purposes. In the dedicated prone biopsy table, the patient lies on the table with the 
breast protruding through a hole in the table. Prone tables are more expensive than 
add-on units and require more room but have several advantages including more 
working space for the operating physicist and less likelihood of patient movement 
due to patient discomfort and vasovagal reactions [20-22]. Conventional or digital 
spot mammographic imaging is available for both types of stereotactic devices. 
Digital imaging reduces the biopsy time and this may increase the likelihood of a 
successful procedure [4]. Stereotactic guidance is the preferred biopsy type for 
microcalcifications but it can be used for all types of mammographic lesions [141]. 
After the biopsy of microcalcifications, specimen radiography needs to be 
obtained to confirm that the lesion in the target has been biopsied [144]. 
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2.7.3 MRI guidance 
MRI-guidance equipments for breast biopsy are commercially available [13, 14], 
however these devices are not yet in widespread use. In addition, MRI-guided biopsy 
requires much time and personnel [145]. Therefore, when a suspicious lesion is 
detected on MRI, it should be re-evaluated by ultrasonography and mammography 
and if detected, it should be biopsied under guidance of these methods [145]. MRI-
guidance is usually performed with stereotactic devices, which usually consist of 
three main components: a compression mechanism, an imaging coil, and an aiming 
device [13, 14]. Core needles and vacuum devices have been used [13, 14] with high 
technical success rates. After the biopsy, a clip marking of the biopsy site is 
recommended for further mammographic follow-up and for possible adjunctive 
surgery [146]. 
 
2.7.4. Fine needle aspiration (FNA) 
Fine needle aspiration has been widely used since the early 80´s in the diagnosis 
of breast lesions [147]. In FNA, cells of the tumour tissue are aspirated for cytological 
analysis using a 20-25-gauge (G) needle [15]. FNA is cost-effective, minimally 
invasive and rapid. At institutions where highly experienced on-site cytopathologists 
are available, sensitivity of 100% and specificities of 96-100% have been reported 
[148]. However, FNA is unable to reliably distinguish invasive carcinoma from in situ 
carcinoma [148, 149]. The false negative rate is relatively high, with lobular 
carcinoma false negative rates of 32% have being published [150, 151]. Also high 
numbers of unclear samples have been reported; in a multicenter study 152 of 429 
samples (35%) were insufficient [152]. FNA is a useful tool for diagnosing cysts if 
ultrasonography fails to reveal typical cyst findings. If the needle tip proves to be 
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within the lesion in ultrasonography and the aspiration is unsuccessful, a solid tumour 
must be suspected [28]. Ultrasonography -guided FNA can also be used for 
diagnostic work-up of enlarged lymph nodes [123]. 
 
2.7.5. Core needle biopsy (CNB) 
CNB, first reported by Parker et al. has largely replaced FNA since the early 90´s 
in the diagnosis of palpable and non-palpable breast lesions [12]. An automated long 
throw 14-G needle is most often used to obtain samples which are 20 mm long and 2 
mm wide, weighting approximately 17 mg [11, 153-155]. In these systems, a cutting 
needle is “shot” rapidly through a breast lesion. After each pass the needle with the 
core is removed and the needle must be reinserted for the next biopsy. In studies 
comparing 14-, 16-, and 18- gauge needles, the diagnostic accuracy increased 
significantly with increasing needle size [153, 154]. Cores acquired with a 14-gauge 
needle allow histopathologic analysis of the tumour tissue, including tumour grade. 
There are also some studies assessing hormone receptor status and HER-2 from 
core samples [156, 157]. Validation studies have revealed 91-97% agreement 
between stereotactic 14-gauge core biopsies and surgery [8, 11, 19, 158] and 100% 
agreement between US-guided 14-gauge biopsies and surgery [4]. The 
recommendation of obtaining five cores for masses and a minimum of five cores for 
microcalcifications has been defined for the biopsy of non-palpable breast lesions 
using a stereotactic prone device [18, 158] and a minimum of 4 cores using US-
guidance [159].  
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2.7.6. Vacuum assisted biopsy  
Vacuum-assisted biopsy devices are attached to a vacuum, which draws tissue 
into a side hole in the probe. Then a rotating cutter advances over the tissue, cuts a 
core from the breast and withdraws the specimen into the system. A vacuum can 
also be used for suction of blood from the biopsy cavity during the procedure. 
Multiple 11-gauge specimens with the average weight 100 mg each, can be obtained 
by rotating the needle sequentially around its axis [16, 17, 28].  
 
2.8. Imaging guided preoperative localization 
Despite of development of percutaneous imaging guided biopsy methods there 
are limitations that need to be taken into consideration e.g. the possibility of false 
negative diagnoses and histopathological underestimations of ADH and DCIS-lesions 
[160]. Lesions causing nipple discharge are usually visible only in galactography and 
need surgical biopsy both for diagnosis of the lesion and for the treatment of the 
symptom (discharge) [25]. Therefore an imaging guided localization and surgical 
excision remains as an alternative for achieving diagnosis of breast lesions.  
 
2.8.1. Percutaneous wire localization 
For example, for lesions that are too close to the chest wall, or in very thin 
breasts, it may be impossible to perform stereotactic biopsy and if these lesions are 
not visible on ultrasonography, the surgical biopsy under guidewire guidance may 
have to be considered [28]. For guidewire localization, mammography with a 
perforated or marked compression plate, stereotaxy or ultrasonography are most 
often used. MRI-guidance is possible for lesions visible only in MRI [28]. According to 
an extensive literature review, mammographically directed needle localized breast 
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biopsies had miss rates of 0-17.9% (mean, 2.6%) [161]. Experience and co-operation 
between radiologists, surgeons and pathologists are essential for successful 
procedures [162].  
 
2.8.2. Preoperative galactography with methylene dye 
According to literature 20%-33% of the surgical biopsies, where the localization 
of the intraductal lesion was based on diagnostic galactography only had no finding 
to explain the discharge [25, 163]. Preoperative galactography performed 
immediately before surgery, using 1:1 ratio of contrast medium and methylene dye 
improved lesion detection to 100% [25]. However, lesions situated deep within small 
peripheral ducts may be difficult to localize with methylene dye, which quickly 
diffuses throughout the breast hindering precise localization for both the surgeon and 
the pathologist [28] and therefore additional localization methods may be beneficial. 
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3. AIMS OF THE STUDY 
 
The main purpose of this study was to evaluate the reliability of 14-gauge 
stereotactic core needle biopsy (SCNB) obtained by an add-on biopsy device in the 
diagnosis of mammographically detected non-palpable breast lesions in terms of 
diagnostic accuracy, number of false negative cases and underestimations of ADH 
and DCIS. In addition, the aim was to evaluate the use of an add-on stereotactic 
device aided by galactography for preoperative wire-localization of lesions visible 
only in galactography. 
 
Specific aims were:  
1. To evaluate the rate of technically successful biopsies as a function of operator 
experience. 
 
2. To determine the number of cores required for adequate histopathologic diagnosis. 
 
3. To compare 14-gauge SCNB with surgery in the assessment of prognostic factors 
of breast cancer (ER, PR and HER-2) and to determine the number of cores needed 
for assessment of these factors.  
 
4. To assess the feasibility and diagnostic performance of stereotactic guided 
galactography aided wire or coil localization of breast lesions in patients with 
spontaneous unilateral nipple discharge.
43 
4. PATIENTS AND METHODS 
 
4.1. Patient selection and study design 
Early in 1998, stereotactic equipment for core needle breast biopsy became 
available in Kuopio University Hospital in Eastern Finland with a catchment area of 
251 000 people. Between April 1998 and January 2001, all patients referred to our 
hospital for suspicious, mammographically detected non-palpable breast lesions 
(small mass lesions, architectural distortions and microcalcifications) that could not 
be detected by using ultrasonography were scheduled for stereotactic guided breast 
biopsy and were enrolled into this study (study I).  
During the study period between June 1998 and January 2001, stereotactic 14-
gauge core samples were collected in three different containers as follows: the first 
sample (the central biopsy) was collected into container A, the second and the third 
samples (obtained 2 mm from the centre of the lesion) into container B, and all 
additional samples were placed into container C. Histological evaluation and report 
were performed for each container separately (study II). 
For invasive cancers, estrogen receptors (ER), progesterone receptors (PR) and 
human epidermal growth-factor receptor (HER-2) were assessed by 
immunohistochemistry for each container separately and for the surgical sample. All 
HER-2 results 2+ and 3+ were scored by chromogenic-in-situ-hybridisation (CISH). In 
the comparisons of different containers and also of surgical specimens, all cases with 
invasive cancer in at least two containers and in the surgical specimen were included 
in the study (study III). 
In addition, between January 2002 and December 2003, all consecutive patients 
with spontaneous, clear, serous or bloody unilateral nipple discharge, normal 
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mammographic and ultrasonographic findings (if achievable) and a filling defect ≥ 3 
cm from the nipple noted on a diagnostic galactography were scheduled for an 
additional galactography examination and immediate stereotactic wire localization or 
coil placement prior to surgery using the filling defect as the target (study IV).  
Between April 1998 and December 2003, altogether 230 patients with 240 
lesions were evaluated in these four studies (Fig.1). 
 
4.1.1. Studies I and II 
Between April and June 1998, all patients referred for SCNB, were included in 
study I for assessment of the learning curve. After this pilot phase, during study II 
period, 661 patients with mammographically detected suspicious breast lesions were 
referred to the hospital. Ultrasound guided core needle biopsy was performed in a 
total of 449 patients. Altogether 212 patients with 220 lesions were scheduled for 
SCNB. Of those, 15 patients were excluded. In seven patients, the location of the 
lesion was high, near the axillary fossa or so close to the thoracic wall and pectoral 
muscle that it could not be reached by the stereotactic equipment. These kinds of 
lesions were excised surgically. In two (1%) patients, the biopsy had to be terminated 
after the first pass because of a vaso-vagal reaction. In five patients, the samples 
were mistakingly all placed in one container instead of three containers, and 
therefore no separate analysis could be performed. In addition, one patient died from 
unrelated causes before any follow-up examination. The remaining 197 patients 
(mean age 56 years, range 32-88 years) with 205 breast lesions (97 mass lesions 
and 108 clusters of microcalcifications) were evaluated in study II. Eight patients had 
two lesions: in seven patients there were two lesions ipsilaterally and one patient had 
a lesion in each breast. 
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Altogether 221 patients (mean age 56 years, range 22-88 years) with 231 breast 
lesions (113 mass lesions and 118 clusters of microcalcification) were eligible for 
study I assessing the learning curve effect. Ten patients had 2 lesions: in 9 patients 
there were 2 lesions ipsilaterally and one patient had a lesion in each breast. 
Twentyfour patients (26 lesions) were examined between April and June 1998, 
and 197 patients (205 lesions) between June 1998 and January 2001. These 197 
patients were the same as those in study II (Fig.1). 
Altogether 149 (73%) of the lesions in study II were found from screening 
mammograms. Forty nine (24%) lesions were found from mammograms obtained 
because of a symptom (lump, pain or eczema somewhere in the breasts) and 7 (3%) 
lesions from mammograms obtained because the patient was receiving hormone 
replacement therapy. 
 
4.1.2. Study III 
The material of study III comprises of a subgroup of the material of study II 
(Figure 1). In study II, there were a total of 54 patients with invasive carcinoma in the 
surgical specimen. Of these, 13 patients with invasive carcinoma detected in none or 
in only one container in SCNB were excluded. Eleven patients had either ductal 
carcinoma in situ (DCIS) (n=7), atypical ductal hyperplasia (ADH) (n=3) or benign 
findings (n=1) in the three containers and 2 patients had invasive carcinoma only in 
one container. Altoghether 41 patients (mean age 61 years, range 42-82 years) with 
invasive cancer in at least two containers were included in study III. In three cases, 
the first container (A) did not contain invasive carcinoma, in three cases the second 
container (B) did not contain invasive carcinoma and in one case no invasive 
carcinoma was detected from the third container (C). Altogether 23 (56%) of the 41 
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lesions were found from screening mammograms. Seventeen (42%) lesions were 
found from mammograms obtained because of a symptom (lump, pain or eczema 
somewhere in the breasts) and 1 (2%) lesions from mammograms obtained because 
the patient was receiving hormone replacement therapy. Mammographically, there 
were 35 (85%) masses and 6 (15%) clusters of microcalcifications. 
According to pathological TNM-classification, 37 (90%) of the tumours were 
classified as T1 and 4 (10%) as T2. Axillary lymph nodes were classified as N0 in 32 
(78%) of the cases, N1 in 7 (17%) of the cases and N2 in 2 (5%) of the cases. 
According to the histopathological grading, there were 17 (42%) grade I tumours, 21 
(51%) grade II tumours and 3 (7%) grade III tumous. 
 
4.1.3. Study IV 
Altogether 9 consecutive patients (mean age 54 years, range 34-75 years) with 
spontaneous, clear, serous or bloody unilateral nipple discharge, normal 
mammographic and ultrasonographic findings (available in 5 patients) and a filling 
defect noted on a diagnostic galactography were included in the study (Fig.1).  
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4.2. Approval of the ethics committee 
The study was approved by the ethical committee of Kuopio University Hospital. 
Informed consent was obtained from all patients. 
 
4.3. Mammographic work-up  
A complete mammographic imaging work-up, including magnification images was 
carried out for all lesions. A comparison with prior mammograms was performed, if 
achievable. Mammographic findings were categorized either as masses, which 
included masses with or without microcalcifications, or as clusters of 
microcalcifications. The size of the lesion was determined as the greatest diameter of 
the lesion measured directly from the mammogram, and was reported in mm. The 
classification of the mammographic findings was independently performed by two 
radiologists with 8 and 9 years of experience in breast imaging who were blinded to 
the histological results. In study I, stereotactic images of unsuccessful biopsies were 
retrospectively analysed to confirm correct targeting of the lesions. 
All lesions were retrospectively categorized according to the standardized Breast 
Imaging Reporting and Data System BI-RADS recommended by the American 
College of Radiology. In cases of discrepancy, a consensus reading was done.  
 
4.4. Stereotactic core biopsy  
All biopsies were performed using a regular mammography machine (Planmed, 
Helsinki, Finland) and a conventional add-on stereotactic biopsy device (Planmed, 
Helsinki, Finland) with the patient in an upright seated position (Fig.2.). Film-screen 
system (Kodak MIN-R 2000) was used. A delay due to film processing was 
approximately 2.5 minutes for each film. Biopsies were obtained with an automated 
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biopsy gun (C.A. Bard, Covington, GA) with a 22 mm throw and a 14-gauge needle. 
The biopsy procedures were undertaken by one of five radiologists all with 4-6 years 
of experience of performing breast biopsies.  
 
 
 
Figure 2. An add-on stereotactic biopsy device with an automated needle. 
 
Four of the radiologists had no previous clinical experience with stereotactic 
breast biopsies prior this study. The remaining radiologist in order to learn the 
technique, had participated in 3 add-on stereotactic core needle biopsy procedures 
under the direct supervision of an attending radiologist at another breast clinic that 
used equipment similar to the hospital, where this study was carried out, in addition 
to practising the technique with a phantom. The other 4 radiologists performed their 
first three biopsies under his direct supervision. All five radiologists performed the 
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subsequent biopsies (after the first 3) independently. The mean number of biopsies 
was 46 (range 11-94) per radiologist (study I). 
In the beginning of the biopsy procedure, the procedure was explained to the 
patient, who was then positioned for the scout images. The patient was given the 
opportunity to hear the noise of the biopsy gun prior to procedure. The biopsy 
direction was chosen by the performing radiologist, after reviewing diagnostic films, 
taking into consideration the best visibility of the lesion in craniocaudal or lateral 
orientation and the shortest biopsy route to the lesion. Once the targeted lesion was 
located on a scout image, the compression was tightened and a pair of stereotactic 
images was obtained with 15˚ angulation for each projection. The target was 
identified and marked on both images. The skin over the lesion was cleaned and 
anesthetized. The core biopsy needle was inserted to the biopsy gun, which was 
then set to the holder of the stereotactic device. A 2-3 mm incision was performed to 
the skin and the needle tip was inserted through the skin at the zero location. For 
mass lesions, after localizing the lesion, the first needle pass was targeted to the 
centre of the lesion. Routine pre-fire stereotactic views were obtained to confirm the 
position of the needle. The needle-tip location was modified, if needed, to ensure a 
central position was achieved. The following 3-4 needle passes were obtained in a 
clock-wise manner 2 mm from the centre. Additional needle passes were obtained 
after individual consideration, depending on the lesion distribution. For 
microcalcifications there was more variability in needle placement. The intent was to 
target the most suspicious area for needle biopsy. If the calcifications were tightly 
clustered, the first pass was obtained either by targeting the centre of the lesion or by 
selecting a particularly distinctive calcification that could be reliably discerned on the 
two stereotactic images. Subsequent passes were planned according to the 
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geography of the calcifications.  
 
4.5. Specimen radiography 
For lesions evident as microcalcifications without any mass, the presence of 
microcalcifications in the biopsy material was confirmed from radiography of the 
specimen or from the histopathologic report. The practise of routine specimen 
radiography was initiated in May, 2000. Radiography was performed for 51/118 
(43%) specimens taken from lesions of microcalcifications in study I and 48/108 
(44%) specimens from lesions of microcalcifications in study II.  
 
4.6. Histopathologic analysis 
Handling of the histological specimens was standardized. Core samples were 
immediately placed into 10% neutral formalin and sent to the Department of 
Pathology, where they were kept in fixative for two to four hours before routine 
processing overnight.  
One of five pathologists all with 7 to 20 years, mean 12 years, of experience with 
breast pathology analysed the contents of each container separately for the presence 
of (1) invasive carcinoma, (2) DCIS, (3) radial scar, (4) ADH, or (4) a specific benign 
diagnosis. The same pathologist analyzed all three containers of each lesion and he 
was not blinded to the study design.  
The fresh surgical specimen was X-rayed to ensure that the lesion was in the 
sample with tumour free margins. Then the specimen was measured, painted and 
sliced within the next half an hour. After overnight formalin fixation, the specimens 
were cut, processed and embedded in paraffin on the following day. Malignant 
tumours were classified according to the TNM classification system and histological 
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grading was performed according to the Nottingham modification of the Bloom and 
Richardson method. 
 
4.6.1. Immunohistochemistry (IHC) and chromogenic in situ hybridisation 
(CISH) 
For invasive carcinoma, hormone receptor, HER-2 and CISH stainings were 
reviewed by the same consultant pathologist with seven years´ experience in breast 
pathology. Double reading was performed for HER-2 staining. In cases of 
discrepancy, a consensus reading was done.  
For ER and PR, the proportion of nuclear staining was quantified from 0 to 100%. 
Staining < 10% was then designated as negative and ≥ 10% as positive. For HER-2, 
the Clinical Trial Assay (CTA) system was used to grade the degree of membrane 
staining. No staining or membrane staining observed in less than 10% of tumor cells 
was given a score of 0. A faint /barely perceptible membrane staining detected in 
more than 10% of the tumor cells was scored as 1+ and a weak to moderate 
membrane staining in >10% was graded as 2+. Strong complete membrane staining 
in >10% of the tumor cells was graded as 3+ which was a threshold for HER-2 
positivity. All 2+ and 3+ results were further investigated by CISH to detect gene 
amplification.  
 
4.7. Preoperative galactography-aided stereotactic wire or coil localization 
(Study IV) 
Diagnostic galactography was performed in patients with unilateral bloody, 
serous, or clear nipple discharge by using standard techniques [129]. 
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For patients with an intraductal filling defect that was not visible on 
mammography or ultrasound, an additional galactography examination was 
performed before surgery. 
The secreting duct was cannulated with the patient in the supine position with the 
ipsilateral arm resting behind the head. First, the nipple and the periareolar area were 
cleansed with an ethanol swab. The orifice of the secreting duct was localized using 
slight periareolar pressure to produce discharge. The ducts were cannulized by 
insertion of a blunt sterile metallic cannula, (30-G curved or straight cannula; 
Galactography Kit, MDTECH, USA) measuring 20 mm in length, gently into the 
secreting duct. The cannula was then connected to small-volume extension tubing 
with a 1 ml syringe filled with water-soluble, non-ionic contrast material. The duct was 
filled with 0.2-2 ml of contrast material by gentle hand injection until resistance was 
felt, the patient experienced discomfort or pain, or there was backflow of the contrast 
material at the nipple. The cannula and the syringe were fixed securely in place with 
a bandage to enable administration of additional contrast material, if necessary, and 
to minimize contrast material leakage. The patient was aided in the transfer from the 
examination table to the mammography unit. Standard orthogonal screen-film 
magnification images were obtained from the retroareolar area to verify that the 
correct duct had been cannulated and to further locate the filling defect.  
The add-on stereotactic device was set in place on the mammography unit. The 
screen-film magnification images just obtained were used to locate the fenestration 
on the compression plate. Two scout images were first obtained from the target area. 
Local anesthetic was injected and the breast lesion localization needle with the wire 
(n=8) (DuaLok, Bard, Covington, USA) or a coil (n=1) (MReye Breast lesion needle 
localization coil, Cook, Bjaeverskov, Denmark) was targeted to the filling defect under 
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stereotactic guidance. A new pair of scout images was taken to ensure the 
localization of the needle tip, which was corrected, if necessary. When the needle tip 
was correctly within the lesion, a wire or coil was passed through the location needle 
and the needle was pulled out. After the procedure, standard craniocaudal and 
mediolateral mammographic views were obtained to verify the correct location of the 
wire and the lesion for the surgeon. All procedures were performed by one of two 
radiologists immediately preoperatively, except for a single coil localization which 
was performed one week prior the surgery. On the operation day, the coil was 
localized with the wire under ultrasonography guidande. At surgery, periareolar 
incision to enter the retromamillary area was performed and an excision was made 
containing the tip of the wire with 1 to 2 cm of the surrounding area. 
 
4.8. Treatment and follow-up 
The histopathology of each lesion was reviewed in conjunction with the 
mammographic findings and the clinical history in a multidisciplinary meeting with a 
radiologist, a pathologist, a plastic surgeon and an oncologist to plan further 
management of the patient. All of the cases with the galactography aided wire or coil 
localization were also reviewed in this multidisciplinary meeting to confirm that the 
lesion identified by galactography was in the surgical sample. 
After core biopsy, all women whose biopsy result indicated the presence of 
invasive carcinoma or DCIS underwent surgical treatment. High-risk lesions, such as 
ADH and radial scars, were also surgically resected, as were benign lesions with 
discordant mammographic findings. All other lesions with benign biopsy results were 
recommended for mammographic follow-up at 1 year and 2 years. 
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5. STATISTICS 
 
In general, continuous variables were tested for normal distribution with the 
Kolmogorov-Smirnov 1-sample test. The Mann-Whitney U test for continuous 
variables with non-normal distributions was used for group comparisons in the case 
of two independent samples and the Wilcoxon Signed Ranks Test in the case of two 
related samples. Chi-square test was used for dichotomized discrete variables. 
Differences were considered statistically significant if the p value was less than 0.05.  
 
5.1. Studies I and II 
The 95% confidence intervals in study II are approximations of the confidence 
intervals (preferred when proportions are near unity or zero) based on formulas given 
in Fleiss et al [164]. The other analyses were performed with the statistical package 
SPSS for Windows, Version 11.5. (SPSS, Inc., Chicago, IL). 
In studies I and II, the calculations were performed separately for mass lesions 
and microcalcifications. The sensitivity and specificity values with 95% confidence 
intervals, and the overall accuracy as well as positive (PPV) and negative (NPV) 
predictive value of the stereotactic core biopsy, were determined using the results of 
surgical samples and mammographic follow-up as a reference standard (study II).  
 
5.1.1. “Strict” and “working” analysis 
Sensitivity, specificity and overall accuracy were separately calculated in two 
categories (study II). (1) “Strict” analysis - Strict sensitivity was defined such that any 
stereotactic core biopsy diagnosis of a non-malignant lesion that after surgical 
excision proved to be malignant was considered as a false negative. (2) “Working” 
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analysis - Working sensitivity was defined such that a stereotactic core biopsy 
diagnosis of ADH or radial scar (high risk lesions) was considered as a true positive if 
the final surgical sample corresponded to the result or showed malignancy (DCIS or 
invasive carcinoma), and a false-positive if the diagnosis in the pathology report of 
surgical excision was benign [165].  
 
5.1.2 Determinations 
5.1.2.1. False negative rate 
False negative rate was determined by dividing the number of cases that were 
negative by the method (core biopsy or surgical sample) and positive by the other 
(reference) method by all positive cases of the reference method.  
 
5.1.2.2. Malignancy rate 
Malignancy rate was calculated by dividing the number of malignancies in each 
BI-RADS category by the number of lesions in each category.  
 
5.1.2.3. Adequate samples 
Samples were considered adequate 1) for microcalcifications, if 
microcalcifications were detected either on specimen radiography or in the 
histopathology of clusters of microcalcification and 2) for mass lesions if 
histopathologic diagnosis in concordance with the mammographic appearance was 
obtained. 
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5.1.2.4. Technically successful biopsies 
In study II, achieving adequate samples, as described above, was considered as 
technically successful.  
 
5.1.2.5. Technically unsuccessful biopsies 
Samples were considered technically unsuccessful 1) for microcalcifications, if 
there were no microcalcifications detected either on specimen radiography or on 
histopathology of clusters of microcalcifications and 2) for mass lesions, if 
histopathologic diagnosis was not concordant with the mammographic appearance of 
the lesion. In addition, the biopsies that yielded a false negative histologic result were 
considered as technically unsuccessful. Also biopsies that had to be repeated were 
considered as technically unsuccessful even if the re-biopsy was successful. 
 
5.1.2.6. Underestimated ADH and DCIS lesions 
Underestimated ADH lesions were defined as lesions that yielded ADH at core 
needle biopsy and carcinoma at surgery [166]. Underestimated DCIS lesions were 
defined as lesions that yielded DCIS at core biopsy and invasive carcinoma at 
surgery [166]. 
 
5.1.2.7. Learning curve 
In the assessment of the learning curve, the rate of technically successful 
biopsies as a function of operator experience was calculated cumulatively for all 5 
individual radiologists, separately for the first 5 independently performed biopsies of 
each radiologist and for all subsequent cases and also separately for the first 5 
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clusters of microcalcifications and for the first 5 mass lesions for each individual 
radiologist (study I). 
 
5.2. Study III 
Statistical differences in the proportions of positive and negative cases between 
the dichotomised ER, PR and HER-2 scores in core samples and surgical specimen 
were evaluated using McNemar´s non-parametric paired proportions test. 
Intertechnique differences were tested by the kappa statistics.  
Containers were dichotomized as negative if all cores in the container were 
negative and positive if at least one of the cores was positive for ER, PR and HER-2. 
Container combinations were designated accordingly; negative if all containers were 
negative and positive if at least one of the containers was positive.  
Sensitivities of the individual containers (A, B and C) and container combinations 
(A+B, A+B+C) for the assessment of ER, PR and HER-2 were calculated. In the 
calculations of sensitivity, the “optimal reference” was used, which was considered 
positive if at least one of the containers or the surgical specimen was positive and 
negative if all three samples and the surgical specimen were negative. 
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6. RESULTS 
 
A minimum of 4 samples (mean 7) were obtained from each patient (study I, II 
and III). The numbers of biopsies performed by each individual radiologist were 94, 
31, 12, 83 and 11 (study I). One patient (0.5%) suffered from a vaso-vagal reaction 
leading to the termination of the biopsy procedure after three passes. The rebiopsy 
was performed without complications. Infections and hematomas requiring further 
treatment were not noted in these studies. One biopsy failed because of patient 
movement (0.5%). The repeat biopsy was accomplished successfully. 
Final diagnosis according to surgery (n=95) and follow-up (n=110) was malignant 
in 86 (42%) cases (54 invasive carcinomas and 32 cases of DCIS) and benign in 119 
(58%) cases (includes two cases of radial scars).  
Categorization of the lesions according to the BI-RADS classification is in Table 
4. 
60 
 
TABLE 4. Number of malignancies in surgical samples and core samples of 
97 mass lesions and 108 clusters of microcalcifications and malignancy rate 
(%) according to the mammographic appearance of lesions classified using 
BI-RADS categorization (Study II) 
 Number 
of lesions 
Number of malignant lesions 
surgery/core sample 
Malignancy rate % 
surgery/core sample 
Mass lesions 97 39 / 40 40 / 41 
BI-RADS 2 0 0 / 0 - 
BI-RADS 3 13 0 / 0 0 / 0 
BI-RADS 4 59 16 / 16 27 / 27 
BI-RADS 5 25 23 / 24 92 / 96 
Microcalcifications 108 47 / 43 43 / 40 
BI-RADS 2 2 0 / 0 0 / 0 
BI-RADS 3 22 0 / 0 0 / 0 
BI-RADS 4 62 28 / 24 45 / 39 
BI-RADS 5 22 19 / 19 86 / 86 
Total  205 86 / 83 40 / 41 
 
6.1. SCNB histology (Study II) 
Histopathological analysis of core samples revealed carcinoma in 83 (40%) of 
the 205 lesions in the whole material, ADH in 3 (1.5%), radial scar in 1 (0.5%) and a 
benign diagnosis in 118 (58%) samples.  
Of the 97 mass lesions (17 with microcalcifications and 80 without 
microcalcifications), the stereotactic core sample revealed malignancy in 40 (41%) 
lesions (invasive carcinoma in 38 cases and DCIS in two cases), radial scar in 1 (1%) 
lesion and a benign diagnosis in 56 (58%) lesions of which one yielded only benign 
breast tissue and was classified as inadequate. No DCIS underestimations were 
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detected. There were no false negative results among the 96 diagnostic core 
samples. Instead, one false positive result occurred. In this one special case, the 
main diagnosis was a radial scar in core samples, but there was a mild suspicion of 
tubular carcinoma. The final surgical diagnosis was a radial scar. The result of a 
repeated retrospective blinded reading of the core samples from this lesion was also 
radial scar. Altogether 13 of 17 (77%) mass lesions with microcalcifications turned 
out to be malignant. 
Of the 108 lesions which were evident as clusters of microcalcification without 
any mass, stereotactic core sample revealed malignancy in 43 (40%) cases (invasive 
carcinoma in 12 and DCIS in 31), ADH in 3 (3%) cases, and a benign diagnosis in 62 
(57%) cases, four of which were inadequate (4%). All three cases with a core sample 
diagnosis of ADH proved to be malignant (two cases of DCIS and one invasive 
carcinoma) at surgery. These three cases were categorized as false negative 
according to the strict analysis (Fig.3). In the fourth strict false negative case, the 
lesion was surgically operated because of discordance between the mammographic 
finding and the histopathologic diagnosis of fibrocystic disease in the core samples, 
and subsequently invasive lobular carcinoma was detected. This was the single false 
negative case in the material according to the working analysis (Fig. 4). The strict 
false negative rate was 4.7% (4 of 86) and the working false negative rate was 1.1% 
(1 of 88). Among the 31 clusters of microcalcifications indicating DCIS at core 
samples, surgery revealed invasive ductal carcinoma in 7 (23%).  
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             a.                                     b. 
Figure 3. (a) Craniocaudal mammogram obtained in a 36-year-old woman shows a 
cluster of microcalcifications (arrow) classified as BI-RADS category 4. (b) Lateral 
mammogram at core sample shows a cluster of microcalcifications (arrow); the 
diagnosis was ADH. At surgery, histologic grade 3 invasive ductal carcinoma was 
revealed. 
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               a.                                          b.  
Figure 4. The first screening mammogram and magnification mammogram obtained 
in a 49-year-old woman revealed a 20-mm-diameter cluster of microcalcifications 
(arrow) classified as BI-RADS category 4 in the upper lateral quadrant of the right 
breast. Diagnosis at core sample was fibrocystic disease. Because of the 
discordance between the mammographic finding and the histopathologic diagnosis at 
core-needle biopsy, the patient underwent surgical excision. LCIS, ALH, fibrocystic 
disease and a small 0.5 x 0.3 cm focus of invasive lobular carcinoma was found. (a) 
Mediolateral oblique view. (b) Area of interest. 
 
6.2. Diagnostic performance of stereotactic core needle biopsy (Study II) 
The diagnostic performance of SCNB for the 3 different containers is shown in 
Table 5.  
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6.2.1. The strict analysis 
The sensitivity of the first sample was 77% (90% for masses and 66% for 
microcalcifications). The result for the first sample was false negative significantly 
more often for microcalcifications (n=16) than for mass lesions (n=4, p=0.01). 
Combined results of containers A and B, i.e. three samples, yielded higher sensitivity 
than the first sample alone: the sensitivity increased to 95% for mass lesions 
(p=0.196) and to 91% for microcalcifications (p<0.001). Multiple samples reached a 
sensitivity of 100% for mass lesions. For microcalcifications, multiple samples did not 
improve the sensitivity (91%) (Table 5). 
 
6.2.2. The working analysis  
The sensitivity of the first sample was 79% (90% for mass lesions and 70% for 
microcalcifications). Three samples yielded a sensitivity of 94 % (95 % for mass 
lesions and 94% for microcalcifications). For the combined results of containers A, B 
and C, a sensitivity of 99% (100% for masys lesions and 98% for microcalcifications) 
was reached (Table 5).  
 
6.2.3. Verification of microcalcifications  
In the samples of clusters of microcalcification (108 lesions) histopathological 
evidence of calcium was detected in 57 (53%) lesions in container A, in 81 (75%) 
lesions in containers A and B combined and in 95 (88%) lesions in at least one of the 
three containers. Radiography was performed on samples taken from 48 (44%) of all 
the 108. The radiography revealed calcifications in at least one sample in 46 (96%) 
lesions. In 9 clusters of microcalcifications (8 patients) there were no calcifications 
seen either in specimen radiographs or in the histopathological analysis. Details of 
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these 9 lesions are included in the paragraph “Technically unsuccessful biopsies” 
(study I). In study I, radiography was performed for 43% (51/118) of the samples 
obtained from lesions of microcalcifications. 
 
6.3. The rate of successful biopsies correlated with the experience of each 
radiologist (Study I) 
The rates of technically successful biopsies for the 5 individual radiologists 
separately for microcalcifications and mass lesions are shown in Table 6. For 
microcalcifications, the rate of successful biopsies was lower for the first 5 biopsies 
than for the subsequent cases and this was true for all radiologists: 75% (18/24) for 
the first 5 biopsies and 88% (79/90) for the subsequent biopsies (p=0.335). For mass 
lesions the rates of successful biopsies were equal: for the first 5 biopsies 96% 
(22/23) and for the subsequent biopsies 96% (79/82) (p=1.0). 
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6.3.1. Technically unsuccessful biopsies  
Technically unsuccessful biopsies occurred in 21 (9.6%) of the 219 
independently performed biopsies; these included more frequently lesions of 
microcalcifications: 15% (17/114) compared with 4% (4/105) of mass lesions 
(p=0.004). For mass lesions, normal breast tissue (n=3) or fatty tissue (n=1) was 
detected on histopathology. In 13 of 17 technically unsuccessful lesions of 
microcalcifications, there were no microcalcifications detected in the specimen 
radiographs or on the histopathologic report. Four of the 17 lesions of 
microcalcifications were false negative at histological examination and were 
classified technically unsuccessful although there were calcifications on specimen 
radiography or histopathology. 
 
6.3.1.1. Surgical excision 
Five of 13 lesions with no microcalcifications detected in the specimen 
radiographs or on the histopathology were surgically excised. In three of these 
lesions, the histologic finding of core biopsy was DCIS or invasive ductal carcinoma, 
which was confirmed at surgery. Two lesions were benign (fibrosis with 
microcalcifications). In one mass lesion with inadequate histopathlogy in core 
samples, surgery revealed fibrosis.  
 
6.3.1.2. Rebiopsy 
Four clusters of microcalcifications underwent successful rebiopsy with a benign 
diagnosis and microcalcifications on histopathology or on specimen radiography. In 2 
lesions, rebiopsy was unsuccessful and no microcalcifications were seen either on 
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specimen radiography or on histopathology. One mass lesion was successfully 
rebiopsied with a diagnosis of fibrocystic disease.  
 
6.3.1.3. Follow-up 
There were two clusters of microcalcifications with unsuccessful biopsies that 
were not surgically excised or rebiopsed. In the follow-up, these lesions as two 
lesions with unsuccessful rebiopsies have remained stable. One mass lesion had 
disappeared at the 6-month follow-up. The remaining mass lesion was still 
unchanged at the 28-month follow-up mammography.  
 
6.3.2. Technically successful and unsuccessful biopsies in different BI-RADS 
categories  
In the comparison of unsuccessful biopsies in different BI-RADS categories for 
mass lesions, the rate was highest in the BI-RADS 3 category (11.8%). For BI-RADS 
4 microcalcifications the rate of unsuccessful biopsies was 18.6%. These lesions 
were smaller (mean 10 mm, range 3-45 mm) than BI-RADS 5 microcalcifications 
(mean 17 mm, range 4-30 mm), but equal to BI-RADS 3 microcalcifications (mean 10 
mm, range 8-15 mm) (Table 7). 
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6.4. Treatment and follow-up (Studies I and II) 
Surgery was performed for 110 of the 231 lesions, and this revealed 18 benign 
and 92 malignant lesions, including one mass with a change detected at the 1 year 
follow-up. Mammographic follow-up was performed for 122 lesions. The mean 
mammographic follow-up time was 24 months (range 6-39 months). Altogether 83% 
(101/122) of the patients were followed-up for 20 months and 64% (78/122) for 24 
months. No patients were unavailable for follow-up, but one patient died and two 
patients moved to another area after adjunctive 6-month follow-up mammography. A 
mammographic change occurred in 2.5% (3 of 122) of the lesions. One mass lesion 
with a core needle biopsy diagnosis of fibroadenoma had grown in the follow-up; the 
diagnosis was fibroadenoma also at surgery. In addition, growth was noted in one 
cluster of microcalcifications and in one mass lesion at follow-up mammography. On 
rebiopsy, the initial diagnosis of fibrocystic disease was confirmed in both cases. No 
change has been noted in the remaining 119 lesions. 
 
6.5. ER, PR and HER-2 assessments (Study III) 
6.5.1. Comparison of core samples with the surgical specimen 
The agreement between core samples and surgical specimens was high: 83% 
for ER, 88% for PR, 88% for HER-2 (IHC) and 93% after adding CISH. Discordant 
cases tended to be positive for core samples, but negative for surgery: 5 of 5 
discordant cases were positive in core samples for PR, 5 of 7 for ER, 4 of 5 for HER-
2 after IHC and 3 of 3 for HER-2 after IHC and CISH, respectively. However, these 
differences did not reach statistical significance (Table 8).  
Cases showing 2+ or 3+ HER-2 overexpression by immunohistochemistry (9 
(22%) surgical specimens and 19 (46%) core samples) were further investigated by 
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CISH. HER-2 gene amplification was detected in 6 cases according to core biopsies 
but only in three cases for surgical specimens.  
When comparing the prognostic assessment based on the surgical specimens to 
that based on the core samples, 5 false negative assessments were made for ER 
(14%) and PR (15%) and 3 false negative assessments for CISH-positive HER-2 
(50%). When comparing prognostic assessments made from core samples with 
assessments made from surgical specimens, 2 false negative assessments were 
encountered for ER (6%), and none for PR and HER-2. Proportions of 
immunohistochemically PR-positive and ER-positive cells from all malignant cells in 
core samples (highest score) were significantly higher than in surgical specimens (for 
ER 74% vs. 63%; p=0.031, for PR 62% vs. 50%; p=0.001) (Fig. 5. a and b). 
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Figure 5. Proportions of immunohistochemically ER-positive (a.) and - PR positive 
(b.) cells from all malignant cells on core samples (highest score) versus surgical 
specimens. Dashed line: x=y 
 
120100806040200-20
120
100
80
60
40
20
0
-20
H
ig
he
st
 c
or
e 
sa
m
pl
e 
sc
or
e 
Surgical specimen r = 0.239 
ER 
Fig. 5a 
Fig. 5b 
75 
6.5.2. Comparison of containers of cores 
When dichotomized as positive or negative, ER assessments for all three 
containers were concordant in 41/41 (100%) of the cases (κ=1.0) and PR and HER-2 
assessments in 35/41 (85%) of the cases (κ=0.66).  
The proportions of ER and PR positive cells relative to all malignant cells in each 
container are shown in figure 6. The containers of cores show a high correlation for 
PR. In discordant cases the proportions are near the cut off value. For ER more 
heterogeneity was detected between different containers. Sensitivities for the 
detection of ER, PR and HER-2 were individually calculated for the three containers 
and container combinations (Table 9). The central core (container A) did not differ 
markedly in sensitivity from the more peripheral cores (containers B and C) in the 
assessment of ER, PR and HER-2. With three cores sensitivity was 95% for ER, 92% 
for PR, 95% for HER-2 (IHC) and 100% after adding CISH. With more than three 
cores sensitivities of 95% for ER, 100% for PR, 98% for HER-2 (IHC) and 100% after 
adding CISH were reached.  
76 
 
Figure 6. Proportions of immunohistochemically ER-positive (a.) and PR-positive (b.) 
cells from all malignant cells in different core samples. Dashed line indicates the cut-
off value of 10% for positive and negative cases. 
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Table 9. Sensitivity (%) of different containers and container combinations for 
the assessment of ER, PR and HER-2 (Study III, 41 patients) 
Container ER PR HER-2 CISH 
A 95 (36/38) 92 (35/38) 89 (34/38) 95 (18/19) 
B 97 (36/37) 92 (34/37) 92 (35/38) 100 (19/19) 
C 95 (38/40) 95 (38/40) 88 (35/40) 90 (18/20) 
A + B 95 (36/38) 92 (35/38) 95 (39/41) 100 (20/20) 
A + B + C 95 (39/41) 100 (41/41) 98 (40/41) 100 (20/20) 
ER = estrogen receptors, PR = progesterone receptors, HER-2 = HER-2 
overexpression, CISH = chromogenic in situ hybridisation. Number of patients are in 
the parentheses. 
 
6.6. Galactography aided stereotactic wire localization (Study IV) 
On galactography, 7 solitary and 2 multiple filling defects were detected. The 
localization procedure was well tolerated by the patients, and no complications were 
noted. All patients that underwent stereotactic-guided wire or coil localization were 
operated by surgical excision of the diseased duct segment. Surgery and subsequent 
histopathological analysis revealed 1 ductal carcinoma in situ (DCIS), 4 solitary 
intraductal papillomas, 2 cases of intraductal papillomatosis, 1 case of mastitis with 
granulomatous tissue and 1 fibrocystic disease with intraductal papillary proliferation. 
In 8 patients, a coexisting ductal ectasia was noted (Table 10). All patients remained 
free of nipple discharge at one year follow-up after surgery. 
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One malignancy was detected: micropapillary DCIS, high grade, with two foci of 
microinvasion (Table 10: patient n:o 6). Surgery was performed under guide wire and 
methylene dye guidance (Fig. 7 A-C). Because of the large, high grade DCIS and 
unclear resection margins, subsequent skin sparing mastectomy with immediate 
reconstruction was performed. 
 
a.      b.                                    c. 
 
Figure 7. 51-year-old woman with brownish bloody discharge from left breast for 6 
months. 
a. Craniocaudal galactography image revealed a duct with multiple branches and an 
ectatic duct segment with a 3 mm filling defect 6 cm from mamilla (arrow) 
b. Enlargement of area of interest (arrow) in a 
c. Immediately after galactography, the craniocaudal mammogram revealed 
adequate stereotactic wire localization, which was performed with ectatic duct as the 
target (arrow) 
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7. DISCUSSION 
 
This study focuses on the validation of an add-on stereotactic guidance method 
for performance of 14-gauge core needle breast biopsies of non-palpable breast 
lesions and for additional use of the add-on stereotactic device for localising lesions 
detected only with galactography. 
 
7.1. Equipment 
Compared to dedicated devices used when the patient is prone, add-on biopsy 
has been thought to be more vulnerable to patient movement and vaso-vagal 
collapses because of the sitting position of the patient. In the present study, only one 
(0.5%) of 205 biopsy procedures had to be terminated because of a vaso-vagal 
reaction. Another two patients were excluded from the study because the procedure 
had to be interrupted after only one pass. The results of this study are consistent with 
those of Caines et al [167] who reported vaso-vagal attacks in 1.6% of their 
procedures, and of Wunderbaldinger et al [22], who reported vaso-vagal collapses 
leading to termination of the biopsy procedure in 2% of the procedures. 
Prone tables have also been advocated over add-on units because the lying 
horizontal position is thought to minimize patient movement [20]. Patient movement 
may make the biopsy procedure more time consuming, and with re-positioning, 
increase the radiation dose. In the present study, only one biopsy failed because of 
patient movement (0.5%). The repeat biopsy was accomplished successfully.  
The current study was performed with conventional film-screen technology with 
an average of 2.5 min time delay due to development of each film. Digital imaging 
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reduces the biopsy time and this may further decrease the incidence of vasovagal 
reactions and the possibility of patient movement [168].  
 
7.2. Classification of mammographic findings 
Core samples were taken from all the lesions referred for biopsy, and BI-RADS 
classification was performed in retrospect. Consequently, some patients with benign 
or propably benign lesions underwent stereotactic core biopsy in this study. Core 
biopsy was performed for two BI-RADS 2 lesions and 35 BI-RADS 3 lesions, with no 
malignancies being detected in these samples. These results are similar to the 
previous reports of a very low incidence of malignancy (0.5-2%) detected among 
lesions categorized as probably benign [169-171] (Table 3). Malignancy was present 
in 36% of BI-RADS category 4 lesions and in 89% of BI-RADS category 5 lesions 
which also is in concordance with the literature [120, 124]. These results support the 
point of view that biopsy is indicated only for category 4 and 5 lesions. 
Pleomorphic microcalcifications within a solid mass need special attention and 
should be considered suspicious for malignancy [172]. In this study 77% of mass 
lesions with microcalcificatios were malignant. 
 
7.3. Diagnostic accuracy of core needle biopsies with an add-on device 
(Studies I and II) 
7.3.1. Strict and working accuracy  
With multiple (>3) cores a strict sensitivity of 95%, strict specificity of 99% and 
overall accuracy of 98% was achieved; the results are similar with those obtained 
with the prone devices (Table 11). The strict false negative rate was 4.7 % (4 of 86) 
for the surgically confirmed malignancies. In previous studies, a false negative rate of 
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4.4% (range, 2.9-6.7%) has been reported, which is comparable to the results of this 
study [8, 9, 11, 18, 173]. All four false negative core needle biopsy diagnoses in this 
study were evident as clusters of microcalcifications, and three of them were ADH. In 
clinical practise, ADH can be calculated as a true positive as was done in working 
calculations, where high sensitivity of 99%, specificity of 99% and overall accuracy of 
99% were achieved. In working calculations there was only one false negative case 
detected. Surgery of this cluster of microcalcifications was performed because of 
discordance between the BI-RADS 4 mammographic appearance and the 
histopathologic diagnosis of fibrocystic disease at core-needle biopsy. Invasive 
lobular carcinoma was found. In previous studies, up to 63.6% of the lesions with 
discordant stereotactic core biopsy and mammography results revealed carcinoma in 
subsequent surgery; the discrepancy is an indication for surgery [174-178]. If one 
wishes to find possible cancers in discordant cases, then it is important to compare 
core biopsy histology with the imaging results in each case [175, 179]. 
A high strict specificity of 99% was achieved in this study in accordance with the 
studies of prone biopsy devices [165]. Only one false positive lesion was detected. In 
this particular case, the main diagnosis was a radial scar at core-needle biopsy, but 
there was a mild suspicion of tubular carcinoma. The final surgical diagnosis was a 
radial scar. The diagnosis was assured by repeated retrospective blinded reading of 
the core specimens. A malignant diagnosis in a core needle biopsy followed by a 
benign surgical diagnosis is usually not considered as false positive [138]. It can be 
explained by either complete removal of the lesion by the core needle biopsy or 
incomplete surgical excision.  
It has to be clarified, that there were 5 lesions in the material classified as true 
negative, that were biopsied technically unsuccessfully with no subsequent rebiopsy 
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or surgery. Instead of mammographic follow-up, these lesions should have been 
surgically excised. The decision was made in the multidisciplinary meeting and was 
not in accordance with the original study protocol.  
 
7.3.2. Underestimation of ADH and DCIS 
ADH is known to underestimate cancer and  warrants surgical excision [3, 160, 
176, 180]. In a series of 1032 lesions diagnosed by core biopsy, Meyer et al [176] 
detected 18 ADH lesions, 10 (56%) of which were malignant at surgery. Similar 
results have been reported by others [3, 10, 177, 180-182]. In this study core needle 
biopsy underestimated the presence of carcinoma in all (3/3) the ADH-lesions.  
Seven of 33 DCIS diagnosed by SCNB proved to be invasive ductal carcinoma at 
surgery. This underestimation rate of 21% is comparable with previous studies with 
figures ranging from 16 to 35%. [3, 10, 136, 183, 184].  
Since most lesions attributable to ADH or DCIS contain microcalcifications, 
histologic underestimates at percutaneous biopsy are most frequently encountered in 
lesions with microcalcifications [180, 182]. 
 
7.3.3. Number of cores 
There is a recommendation of five cores for masses and a minimum of five cores 
for microcalcifications in the biopsy of non-palpable breast lesions with dedicated 
prone equipment [18, 158]. A minimum of four specimens should be obtained with 
ultrasonography guided core-needle breast biopsy and a 14-gauge needle [159]. The 
experience in this study with an add-on device is in line with these recommendations. 
Strict accuracy after a single sample had been removed was 90%, after 3 samples 
this rose to 97% and after more than 3 (multiple) samples were removed, to 98%. For 
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masses the strict sensitivity after a single sample had been removed was 90%, after 
three samples this rose to 95% and after multiple samples were removed 100% was 
reached. However, these results do not provide data to indicate on how many more 
than three samples are sufficient. For microcalcifications the strict sensitivity was 
lower; 66% after a single sample and 91% after three samples, respectively. The 
access to multiple samples did not provide any improvement in the strict sensitivity 
(91%) though an acceptable working sensitivity of 98% was reached. This is again 
explained by the three cases in which core needle diagnosis remained ADH even 
after multiple samples, and surgery revealed carcinoma. The reported strict 
sensitivity rates for different numbers of cores acquired with a prone biopsy table and 
an add-on device are shown in Table 11.  
One of the limitations of these studies (I - III) was, that the number of cores 
obtained was not standardised. If the number had been standardised and the 
samples collected in separate containers each as in previously published studies 
performed using a prone device, it would have been possible to determine the 
minimum number of cores needed to attain a reliable histologic diagnosis. The 
decision to place the cores in three different containers instead of for example five 
containers was partly based on economical considerations. 
The other important limitation of these studies was that the pathologists who 
interpreted the samples were not blinded to the study design, nor were they required 
to analyze the samples in alphabetical order (that is, to record an interpretation for 
sample A before looking at specimen B, and then to record an interpretation for 
sample B before looking at sample C). This kind of study design creates the 
opportunity for observer bias from the pathologist. 
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7.3.4. Technically unsuccessful biopsies 
The majority of the technically unsuccessful biopsies (13/21) in Study I occurred 
with microcalcifications. For lesions evident as microcalcifications, the calcifications 
need to be identified on specimen radiographs; if they are not evident, then rebiopsy 
is clearly warranted [179, 186]. One limitation of this study was that specimen 
radiographs were available only in 44% of the core biopsies (Study II). The presence 
of microcalcification was mainly confirmed from the histopathology of the cores. 
Dahlstrom et al [187] noted that calcifications of < 100 µm assessed histologically 
were not visible on specimen radiography and may thus not represent the 
calcifications seen mammographically. Stomper et al [188] reviewed mammographic 
and histopathologic features of 27 breast cancers that presented mammographically 
as noncalcified masses. The histopathology revealed that 41% of these lesions 
exhibited microscopic calcifications in the tumours or in adjacent tissue. 
Microcalcifications 50-100 µm are seen histopathologically and microcalcifications > 
150 µm can be seen on mammography. The histopathologic size of the calcium 
particles was not measured in the present study. 
Thus, if biopsies of microcalcifications would have been continued until positive 
specimen radiography in every case the number of unsuccessful biopsies would 
undoubtedly have been smaller and the diagnostic accuracy higher. With an add-on 
device, it is impossible to verify that the core sample contains microcalcifications 
during the biopsy procedure without a specific specimen radiography cabine. The 
patient should be released from the biopsy device which also should be taken off 
from the mammography machine to be able to use the equipment for imaging the 
core samples. The continuation of the procedure again, if the samples did not contain 
microcalcifications, takes time and may be impossible because the possible 
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hematoma of the biopsy site may make microcalcifications invisible, and also 
because of the timetables of the hospital. With a dedicated prone device these 
problems may be avoidable, because the separate mammography machine can be 
used for specimen radiography during the biopsy procedure. Nevertheless, specimen 
radiography is considered as a necessity and this study also emphasizes the 
advantages of specimen radiography for all lesions with microcalcifications. In this 
study, failure to retrieve microcalcifications occurred in 11% (13/114) of lesions, a 
result similar to that of Jackman et al who used a prone device [179].  
Visualization of microcalcifications on specimen radiography does not 
necessarily quarantee adequate sampling and correct diagnosis. In study I, in four of 
the 17 technical failures of microcalcification cases, there were microcalcifications 
detected on specimen radiography or in histopathology of the cores, but the 
histopathologic diagnosis was false negative. On the other hand, in 13 cases no 
microcalcifications were detected in the samples, but in three of these lesions, the 
histologic finding of core samples was DCIS or invasive ductal carcinoma, which was 
confirmed at surgery.  
The comparison of technically unsuccessful biopsies in different BI-RADS 
categories revealed that the biopsy of BI-RADS 4 microcalcifications was the most 
demanding, a result in agreement with recent report using a prone device [179]. In 
this study, these lesions were smaller than BI-RADS 5 microcalcifications. Also 
appearance of BI-RADS 4 microcalcifications is often amorfic with round or 'flake' 
shaped calcifications that are small or hazy in appearance [60] whereas BI-RADS 5 
calcifications have more conspicuous linear, branching of pleomofic appearance 
[122]. Liberman et al noted that the failure to retrieve calcifications was significantly 
more likely in small (5 mm or smaller) lesions and in calcifications with amorphous 
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morphology [186]. Special attention should be paid during the biopsy of BI-RADS 4 
microcalcifications that there is truly representative sampling (Table 7).  
Mass lesions were a minority among unsuccessful lesions (n=4). Normal breast 
tissue was the core biopsy diagnosis in three of these cases and fatty tissue in one 
case. One of these lesions was removed surgically (fibrosis) and one was re-biopsied 
(fibrocystic disease). One lesion disappeared by the time of 6-month follow-up. The 
remaining mass lesion was unchanged at the 28-month follow-up mammography. 
Verkooijen et al [137] in their multicenter study of 984 stereotactic core biopsies 
performed for mammographically suspicious non-palpable lesions found that in 5 of 
30 (17%) core biopsy results of normal breast tissue, malignancy was detected at 
subsequent surgical excision. They calculated that the predictive value of normal 
breast tissue is 83% (95% CI 65-94%) and they thus recommended repeated biopsy 
or surgical excision if core biopsy diagnosis is benign tissue.  
 
7.3.5. Operator experience (Study I) 
There are many studies analysing learning process of different medical 
procedures, which have shown improvement in outcome as the phycisians gain 
experience [189, 190]. 
The existence of a learning curve for stereotactic breast biopsy has been 
suggested previously [18, 180, 191]. All these studies have been performed using 
dedicated equipment with the patient in the prone position. The biopsy procedure 
may be more challenging for the performing radiologist if an add-on stereotactic 
device is in use with the patient in a sitting position and thus vulnerable to vasovagal 
reactions and movement. 
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In their multi-institutional study of stereotactic 14-G core biopsies, Brenner et al. 
[18] found a higher frequency of failing to diagnose the lesion when the procedure 
was still novel (defined as the first 20 cases per institution) than during later 
experience. Liberman et al. [191] detected a significantly lower technical success rate 
for the first 5 cases of each radiologist than for subsequent cases (83.3%, versus 
95.3%, p<0.02) as well as for the first 20 cases compared to subsequent cases 
(90%, versus 95.9%, p<0.05) in their extensive retrospective analysis of 923 
stereotactic core biopsies. The false negative rate was higher for the first 15 cases 
than for subsequent cases (p<0.06). For 11-gauge vacuum-assisted biopsy, a 
significantly lower technical success rate was also seen for the first 5 cases than for 
subsequent cases (85% versus 96.3%, p<0.05) and for the first 15 cases compared 
to subsequent cases (90.0% versus 96.5%, p=0.03). In the study entitled “Cancers 
not diagnosed at stereotactic 14-gauge core needle biopsy”, 4/5 (80%) of the cases 
in which inaccurate needle placement led to failure to diagnose cancer occurred 
during the first 9 months after the procedure had been introduced [180]. In a study of 
stereotactic guided 14-gauge vacuum-assisted biopsy, a higher frequency of failure 
to retrieve calcifications during the first 4 months of experience compared to the 
second 4 months was noted [192]. The frequency of imaging-histologic discordance 
was significantly higher in the first 2 years than in later years (5.0% versus 2.7%, 
p<0.04) [175]. Liberman et al [144] found in their study of radiography of 
microcalcifications that experience is a strong contributing factor in calcification 
retrieval, which is supported by the results of this study. Technically unsuccessful 
biopsies occurred significantly more often for microcalcifications than for mass 
lesions (p=0.004) and there was a tendency towards a lower rate of successful 
biopsies for the first 5 biopsies compared to for subsequent cases, but the difference 
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was not statistically significant (75% versus 88% p=0.335). For mass lesions, there 
was no learning curve effect detected. In the present study the performing radiologist 
decided the needle placement for clusters of microcalcifications after individual 
consideration. The intent was to target the most suspicious area for needle biopsy. 
Stereotactic images of unsuccessful biopsies were retrospectively analysed. The 
targeting of the lesions seemed to be correct. The difficulty of sampling 
microcalcifications reflects the geometry and histologic heterogeneity of these lesions 
[193], which makes the biopsy challenging. It seems that the targeting and retrieval of 
calcifications is more successful after gaining experience of estimating these lesions. 
These findings also emphasize the importance of supervision, especially for the 
biopsy of microcalcifications. To improve the calcification retrieval rate, experience in 
performing biopsies of microcalcifications should be gained under the guidance of a 
qualified mentor, also with respect to vacuum assisted biopsies [191]. Three guided 
biopsies are too few. 
One limitation of Study I was, that two of the radiologists performed rather few 
biopsies, which prevented a more detailed analysis of steepness of the learning 
curve. 
 
7.3.6. Follow-up 
Only recently has long-term follow-up information about benign lesions 
diagnosed by stereotactic core needle biopsy been published. Lee detected 
mammographic change at 6-55 months (mean, 20 months) in 21 of 298 cases (7%), 
in which two (0.7%) malignancies were noted [194]. Jackman et al undertook an 
extensive follow-up study in which 307 (99%) of 310 lesions with benign diagnosis at 
14-gauge stereotactic core biopsy were followed-up mammographically and reported 
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26 (9%) cases with progression noted in the follow-up mammography at 6-85 months 
(mean, 55 months), two (0.7%) of which were malignancies [160]. In the large multi-
institutional study of core needle biopsy with clinical and imaging follow-up in 2456 
patients, Parker and colleagues noted a change in 27 lesions, 5 (2%) of which were 
malignant [20]. In a follow-up study of 752 lesions biopsied by 11-gauge stereotactic 
vacuum device, 3 lesions exhibited progression and 3 additional lesions were 
surgically removed but with only confirmation of benign diagnoses; no carcinomas 
were detected during 6-67 months (mean, 24 months) follow-up [139]. In this study, 3 
out of 122 patients have displayed progression in the follow up mammography 
(mean, 24 months), but no malignancies have been detected. The follow-up time 
may not yet be sufficient, since the optimal length of the follow-up remains 
controversial [194, 195]. 
 
7.4. Accuracy of ER, PR and HER-2 assessments (Study III) 
Detailed preoperative histopathologic information is useful for patients who would 
benefit form neoadjuvant chemotherapy and also for prognostic purposes. With 
concordance of 83% for ER, 88% for PR and for HER-2 (IHC) and 93% after adding 
CISH, the results of this study showed good correlation with assessments from core 
biopsies of those from surgical specimens. There are only a few published studies 
which have compared the assessment of prognostic factors of core samples to 
surgical specimens (Table 12). These publications are in line with the results of the 
present study. However, the heterogeneous expression of prognostic factors in 
tumour tissue has been suspected to be a confounding factor in the estimation of 
cores [157, 196] and therefore the surgical sample has remained the gold standard in 
any assessment of ER, PR and HER-2. 
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7.4.1. ER 
A study of 51 core samples and subsequent surgical specimens reported that in 
the surgical specimen, the ER staining was less profound in the centre than on the 
edges of the tumour. The same tendency was not noted on the microscopy of cores. 
It was argued that this might be due to either homogenous fixation of the cores or 
there could be a higher chance of sampling the peripheral part of a tumour using core 
biopsy [201]. In this study, the first needle pass that was always targeted to the 
centre of the tumour did not differ from the more peripheral needle passes. This may 
be due to the small tumour size (12 mm, range 5-27 mm) which promotes rather 
homogenous fixation also for the surgical samples. In addition, immunoreactivity for 
both ER and PR was significantly higher in core biopsies than surgical samples, 
which may reflect the better preservation of the antigens with rapid fixation 
achievable with the cores. In the comparison of proportions of positive ER staining, 
some heterogeneity was noted between individual cores (Fig 6a). When comparing 
values dichotomized as positive or negative, the three different containers were 
concordant in all cases for ER. 
 
7.4.2. PR 
In the comparison of proportions of positive staining for PR, heterogeneity 
between different cores was even less obvious than that seen with ER. However, for 
PR, there were 6 discordant cases between containers, the majority (4) of which 
were near to the chosen cut-off value of ≥ 10% (Fig. 6b). The commonly used cut-off 
points of 10% to 20% for positive and negative ER and PR assessments are 
somewhat arbitrarily selected. Harvey et al [202] reported that including patients with 
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as few as 1-10% weakly ER-positive cancer cells led to significantly improved 
response to endocrine therapy.  
 
7.4.3. HER-2 
Tumours with HER-2 overexpression or amplification have been noted to 
respond to trastuzumab therapy, which lately has been increasingly used as an 
adjuvant treatment for early breast cancer [88-90]. Reliable HER-2 assessment is 
crucial in order to select the true HER-2 positive patients to receive this possibly life-
saving therapy and not to unnecessarily expose non-responders (HER-2 negative 
patients) to the potentially serious adverse effects [89, 90].  
Because of the tendency for false positive results [94], ICH 2+ and 3+ results 
have been recommended to have further confirmation by FISH or CISH for detection 
of gene amplification [96, 203]. HER-2 overexpression or amplification is detected in 
9 to 30 percent of breast cancers [80]. According to results of this study, HER-2 
immunopositivity (3+) was suspected in 24% of the core biopsies, but after CISH-
confirmation, HER-2 gene amplification proved to be present in 15% of the cases, a 
result similar to other reports.  
 
7.4.4. Number of cores for reliable assessment of ER, PR and HER-2  
With three cores (containers A and B) sensitivity of 100% was reached for HER-2 
after adding CISH and with more than three cores, sensitivities of 100% for PR and 
95% for ER were achieved. There were two cases where ER-assessment was 
positive in surgical specimens but negative in core samples. The probable 
explanation for the discordance in these two cases was that handling of the cores 
had not been optimal and may have lead to receptor destruction. Thus, in ER-
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negative cases, the receptor status should be confirmed from the surgical sample. As 
far as I know there are no published studies in which hormone reseptor and HER-2 
assessments have been performed from systematically obtained, separate core 
samples to be able to determine the number of cores needed for reliable 
assessments of these factors. 
 
7.4.5. False negative rates for ER, PR and HER-2 assessment  
In this study, core samples seem to be at least as sensitive as surgical 
specimens in the assessment of ER, PR and HER-2. A similar trend has been 
detected by some other authors [156, 157, 197-199, 204] (Table 12). In the 
comparison of core samples and surgical specimens, false negative rates for surgical 
specimens were 14% in the assessment of ER, 15% in the assessment of PR and 
50% in the assessment of HER-2 by CISH. Gene amplification was detected by CISH 
in 6 core samples, whereas only 3 surgical samples indicated gene 
amplification.Thus 50% of the HER-2 positive cases would have remained 
undetected if HER-2 assessment by CISH had been restricted to surgical samples as 
is the routine in most centres. With respect to the core biopsies, false negative rates 
were lower (6%, 0% and 0%, respectively). Interestingly, Wood et al [200] in a recent 
study achieved contradictory results for PR and HER-2 immunohistochemistry (Table 
12). However, in their study HER-2 results were not confirmed by FISH or CISH. It is 
well known that a large range of factors affect IHC staining results including factors 
related to specimen handling and fixation, techniques used in antigen retrieval and 
staining and interpretations of stainings. In this context, it is important for each 
laboratory to know its own IHC staining results for both core biopsies and surgical 
specimens to be able to use the most sensitive method.  
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The main limitation of this study is the small number of invasive cancers 
decreasing the statistical power. Because the intention was to investigate tumour 
heterogenity and to define the number of cores needed for reliable ER, PR and HER-
assessments, only cases with invasive cancer both in at least two containers and in 
surgical specimen were included. In any case, with resepect to diverse results on the 
field, larger, standardized studies are needed. 
 
7.5. Galactography aided guide-wire or coil localization (Study IV) 
Unilateral spontaneous bloody or clear nipple discharge from a single duct may 
be the first sign of breast carcinoma [23-25]. Therefore it has been considered an 
indication for surgical resection of the pathological duct area. Galactography is a 
method of choice for detecting intraductal pathology. In the absence of abnormalities 
in physical examination, mammography or ultrasonography, the conventional 
preoperative localising methods (palpation, ultrasonography or stereotactic guided 
wire localization) cannot normally be used. 
Galactography alone may not provide adequate guidance for surgery. Baker et 
al. [163] reported that in 6 of 30 cases the abnormalities identified with galactography 
could not be confirmed in the surgical pathology. This is particularly the case for deep 
lesions, where the position of the galactographic lesion imaged in the compressed 
breast may be different in the non-compressed supine breast on the operating table. 
Traditionally, surgical resection has been performed with perioperative methylene 
dye marking of the secreting duct. The duct may also be visualized 
galactographically immediatelly preoperatively by using a combination of contrast 
media and methylene dye [28]. Retromamillary tumours can usually be easily found 
with these techniques, but more proximal lesions may be difficult to detect in the 
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operating theatre, especially in large breasts. Methylene dye quickly diffuses from the 
ductal system into breast tissue [28], and this may potentially lead to over-excessive 
excisions. In cases of small breasts or benign findings, overly large excisions may 
not be acceptable because of the possible deformity of the nipple area complex. With 
mammographic wire localization immediately after galactography, the filling defect 
can be marked for the surgeon to avoid incomplete or excessive resection. In 
addition, the presence of a wire in the surgical sample may help the pathologist in 
locating the lesion.  
Lesions causing intermittent discharge are often difficult to localize. If there is no 
discharge during the operation, the pathologic duct may remain undetected. In case 
of known interminttent discharge, stereotactic guided localization of the filling defect 
with a coil immediately after a successful galactography may be beneficial despite of 
more time-consuming procedure and the use of ionizing radiation. The coiI is readily 
marked with a wire for further surgery, when needed. In the present study a single 
coil localization of a lesion causing intermittent discharge was performed one week 
prior to surgery. On the operation day, the coil was successfully localized with a wire 
under ultrasonography guidance; the localization would have also been possible 
under stereotactic guidance. More cases are needed to validate this method. 
Rissanen et al. [205] reported a series of 52 patients with abnormal nipple 
discharge. An echogenic intraductal tumour was ultrasonographically visualized in 36 
(69%) of the cases: eighty percent of papillomatous lesions, 58% of other benign 
lesions and 20% of malignant lesions were identified. If pathology is detected in the 
ultrasonographic assessment, then the primary localization of the lesion can also be 
performed by ultrasonography to avoid unnecessary ionising radiation. In the present 
study, ultrasonography was performed for 5 patients, all with normal findings. 
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7.6. Vacuum assisted biopsies; Future aspects 
This study was performed before the vacuum-assisted biopsy device was 
introduced in clinical practice in Kuopio University Hospital. In recent years, 
stereotactic biopsy has been increasingly performed with the assistance of novel 
devices, such as vacuum-assisted 11-gauge needles, that acquire a larger volume of 
tissue. Compared with 14-gauge core-needle biopsy, 11-gauge vacuum-assisted 
device has been noted to be advantageous in calcification retrieval [178, 179, 186], 
to have a lower frequency of histological underestimation [206, 207] and has been 
shown to lead to a lower rebiopsy rate [177]. In a retrospective analysis of 1701 
consecutive nonpalpable microcalcification lesions, Jackman et al [179] noted that 
failure to retrieve microcalcifications occurred in 1% (19/1423) of lesions with 11-
gauge vacuum assisted biopsy, in 4% (4/96) of lesions with 14 -gauge vacuum 
assisted biopsy and in 16% (30/182) of lesions with 14-gauge core needle biopsy. 
Nowadays vacuum assisted 11- gauge biopsy is considered as state-of-the-art in the 
biopsy of microcalcifications. With twelve specimens maximum diagnostic yield is 
achieved [208]. 
For mass lesions, the diagnostic accuracy of 14-g core biopsies is very high for 
both prone and add-on devices [8, 20, 22, 158], as verified also in the present study. 
Therefore, core biopsies are likely to remain the primary biopsy method for mass 
lesions. 
Expensiveness is a disadvantage of the vacuum system: the disposable material 
costs 10 – 20 times more than the corresponding material of the 14-g stereotactic 
device.  
In addition to its validation with an add-on device, it would be interesting to know 
if results equal to or even better than those obtained using 14-gauge core biopsies 
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for ER, PR and HER-2 assessment can be achieved by means of vacuum assisted 
biopsies with their larger sample size. However, value of vacuum biopsy in 
prognostic factor assessment may remain reduced, because it is most often 
performed for microcalcifications with malignancy usually detected at preinvasive 
stage [209]. At present, hormone reseptor and HER-2 assessments have influence in 
treatment decisions for patients with invasive carcinoma only. 
Recently promising results have been reported with the use of vacuum assisted 
biopsy both to diagnose and treat intraductal lesions causing nipple discharge. 
Dennis et al. [210] described a technique in which an ultrasonography-guided 
mammotome biopsy was performed immediately after galactography. The discharge 
resolved in the majority (97.2%) of the 38 patients after the biopsy. Guenin [211] 
performed stereotactic vacuum-assisted biopsy immediately after galactography in 5 
patients; in all of them benign papilloma was diagnosed. In four of those patients 
nipple discharge ceased after the biopsy, one patient underwent surgical excision for 
atypia detected within the papilloma. These new techniques are promising in the 
diagnosis and treatment of solitary lesions. Multiple lesions, if they are located in 
distant spots or in many duct branches, may require surgery for complete removal.  
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8. SUMMARY AND CONCLUSIONS 
 
The main purpose of this study was to evaluate an add-on stereotactic guidance 
method for the performance of 14-gauge core needle breast biopsies of non-palpable 
breast lesions by means of investigating the learning curve and number of cores 
needed to achieve a reliable diagnosis. In a study of invasive cancers, different 
numbers of core samples were compared to surgical specimens in the assessment of 
ER, PR and HER-2. A total of 221 patients with 231 breast lesions were included in 
these studies. As a whole, the add-on stereotactic device proved to be well 
comparable with the published results of dedicated prone device in terms of 
diagnostic accuracy, false negative cases and underestimations of histologic 
diagnosis (DCIS and ADH). In a subgroup of 41 invasive cancers, core samples 
seemed to be at least as sensitive as surgical specimens in the assessments of ER, 
PR and HER-2. 
This study also describes galactography-aided stereotactic wire localization 
preoperatively in 9 patients with spontaneous clear, serous or bloody nipple 
discharge. 
 
On the basis of the present study, the following conclusions can be drawn: 
 
1. The results of this study support the existence of a learning curve in the biopsy 
of microcalcifications, in which the majority of technically unsuccessful 
biopsies occurred. More than three mentor-guided biopsies are needed. 
2. More than three samples are needed for a histologic diagnosis of a mass 
lesion. For microcalcifications, an acceptable sensitivity is reached with more 
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than three samples, if the tendency for the core biopsy to underestimate ADH 
lesions is taken into account and these, as well as mammographically and 
histopathologically discordant lesions, are surgically excised. 
3. Stereotactic 14-gauge core biopsy seems to be at least as sensitive as 
surgery in assessment of ER, PR and HER-2. Three cores are needed for 
reliable assessment of HER-2 after adding CISH and more than 3 cores for 
HER-2 (IHC) and PR, possibly due to tissue heterogeneity. For ER sensitivity 
remained lower, 95%, even in multiple cores, therefore ER-negative cases 
should be further investigated from surgical specimens.  
4. Galactography-aided stereotactic wire or coil localization can be successfully 
used to localize intraductal lesions not detected on mammography or 
ultrasonography. 
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